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ABSTRACT
Inflammatory diseases have a huge economic impact on the healthcare system.
Incidence of obesity and muscle atrophy, two high-profile inflammatory diseases,
continues to increase, and anti-inflammatory agents are potential therapeutics for these
diseases. Resveratrol is a polyphenol that has anti-inflammatory effects; however,
resveratrol suffers from low bioavailability and hasn’t had impressive clinical results when
delivered orally. Mannose is a monosaccharide that also has anti-inflammatory effects,
however, effects are highest when mannose is presented on the surface of a support the size
of a bacteria. Incorporation of resveratrol and mannose into biodegradable polymer
microparticles could be a feasible approach to overcome these drawbacks for treating
inflammatory diseases. The most commonly used polymer for FDA approved
microparticle formulations is poly(lactide-co-glycolide) (PLG) and the most common
fabrication technique is the oil in water (O/W) emulsion solvent extraction method. The
objective of this work was to fabricate and optimize resveratrol-encapsulated and mannosepresenting PLG particles using the O/W emulsion solvent extraction method, and to study
particle effects on cells involved in inflammation.
Here, we show resveratrol can be encapsulated in PLG microparticles to a high
extent and particles decrease lipid load in adipocytes grown in culture. We found that
incorporation of resveratrol in the particle formation process causes nonspherical
morphology, which is notable because stable emulsions are known to form spheres.
Nonspherical morphology was dependent primarily on resveratrol and cosolvent
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concentration, and it was found that nonspherical morphology was unique to resveratrol
among several stilbene small molecules. Nonspherical morphology of particles has been
shown to have biological implications, and addition of resveratrol to oil in water emulsions
could be a simple method for conveying nonspherical morphology to particles fabricated
with an already FDA approved method.
Many bioactive agents, such as mannose, bind cell surface receptors, and PLG
particles can act as a support for these agents to promote cell signaling. Mannose was
attached to the surface of PLG microparticles using a novel process. We chemically
modified poly(vinyl alcohol) (PVA) using isothiocyanate chemistry and used this PVA as
the emulsifier in the fabrication system, which will spontaneously coat the surface of
particles. Mannose-presenting particles bound macrophages, colocalized with the mannose
receptor and directed macrophages to secrete factors that led to increased myotube
formation, a key step in muscle regeneration. This process can be used as a new method
for achieving surface functionalization and for treating inflammatory diseases.
Taken together, this work demonstrates the versatility of PLG as an immune
modifying material. This work also demonstrates a new method for tuning morphology of
polymer particles using resveratrol in the O/W emulsions, and a new method for attaching
surface ligands through modifying PVA. In addition to treating obesity and muscle atrophy,
adding resveratrol to PLG particles for tuning morphology and using PVA for surface
functionalization are innovations that could be easily implemented in already FDA
approved formulations, and could have far-reaching applications in this growing sector of
the pharmaceutical industry.
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CHAPTER 1
BACKGROUND AND SIGNIFICANCE

1.1 Inflammatory Diseases
Inflammation is associated with a vast array of conditions, including cardiovascular
disease, type 2 diabetes, cancer, obesity and muscle atrophy1. Inflammatory states can
potentiate the disease itself, such as in the case of obesity and muscle atrophy2,3. It is still
not completely understood why inflammation is associated with these diseases1, but it is
recognized that anti-inflammatory therapies can be beneficial in treating obesity and
muscle atrophy, which are highly prevalent in the U.S.
Obesity is an inflammatory disease that is a comorbidity to many of the leading
causes of death in the U.S4. Obesity is defined as a body mass index over 30 and is
considered an epidemic in the United States according to the CDC5. The healthcare costs
of treating the disease were $147 billion in 2008. By 2017 and 2018 42.4% of the American
population was obese, which was an increase of 36% from as recently as 20145. New
treatment methods and approaches are needed for this public health crisis. Obesity is
characterized by an increase in size and number of fat cells (adipocytes) in body fat
(adipose tissue) and also inflammation which potentiates the disease6. Treatment strategies
for obesity currently include diet and exercise, prescription medication, and invasive
surgery -- in that order depending on the severity of the case4. Each of these treatments
suffers from downsides: diet and exercise changes typically suffer from low compliance;
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prescription medications so far have resulted in bad side effects; and invasive surgery is
typically considered a last resort. As such, new strategies are being developed to address
some of these drawbacks7,8. Treating the adipose tissue with anti-inflammatory drugs may
have positive outcomes in obesity. However, many anti-inflammatory drugs are
hydrophobic molecules that have low solubility and low bioavailability8. New methods are
needed for delivering anti-inflammatory drugs to the adipose tissue.
Muscle atrophy, the loss of muscle mass, is also a condition that is characterized by
inflammation9. Sarcopenia is the type of muscle atrophy associated with aging10. An oftencited report suggested sarcopenia cost the U.S. $18 billion in 2000 which was 1.5% of total
healthcare costs11. Muscle injuries have increased over the last 20 years, especially as the
U.S. population ages and more elderly patients require healthcare services12. Current
treatment strategies for muscle atrophy include exercise and several supplements such as
Vitamin D13. Few treatment strategies exist beyond exercise and supplements, and when
they fail there are not many options. Therefore, muscle atrophy is a condition that needs
more attention and treatment strategies.
1.2 Macrophages and inflammatory diseases
Macrophages play vital roles in almost all tissues in terms of regulating
inflammation, hormone levels and general homeostasis14. They are incredibly plastic and
functionally diverse, owing to their need to be phagocytic in some cases and regenerative
in others15. In some inflammatory disease states it is thought that an effective treatment
could be to induce macrophages to become more anti-inflammatory16.
Many methods have been studied for inducing anti-inflammatory phenotype in
macrophages, primary among them is treatment with Interleukin 4 (IL-4)17. However, IL-
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4 treatment is not a very translatable approach, as recombinant IL-4 (and other cytokines)
are expensive and bolus injections of proteins are metabolized quickly and can have toxic
effects18,19. A simple option is to administer anti-inflammatory small molecules that have
similar effects as IL-4. Another method for inducing an anti-inflammatory phenotype in
macrophages is activating the mannose receptor (MR) (also known as CD206)20. MR is
activated by the monosaccharide mannose, and MR clustering was shown to promote antiinflammatory cytokine secretion in macrophages21. “Reprogramming” macrophages into
an anti-inflammatory phenotype using anti-inflammatory compounds for treatment of
diseases such as obesity and muscle atrophy is a concept that could have promise but has
not been fully studied.
One such anti-inflammatory compound that could benefit inflammatory diseases is
resveratrol. Resveratrol is a natural polyphenol found in wine, grapes and peanuts22. It is
thought to be the compound that gives wine beneficial properties23. Resveratrol is a an
anti-inflammatory and antioxidant compound, and it has also recently been shown to be
an exercise mimetic24,25. Resveratrol was shown to reduce body fat and improve glucose
tolerance in mice26. It has also had delipidating effects in adipocytes grown in vitro27.
However, resveratrol has problems with low bioavailability in humans and has required
large doses in clinical trials28,29. Walle et al. found that after a 25 mg dose of resveratrol
was consumed, only 5 ng/mL of resveratrol could be detected in the plasma. New methods
are needed to achieve therapeutic levels of resveratrol in the target tissues for treatment of
inflammatory diseases.
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1.3 Biodegradable Polymer Microparticles for Biomedical Applications
Biodegradable polymer microparticles were developed as drug delivery vehicles in
the 1970s to improve the delivery of drugs with low solubility, low bioavailability, toxic
effects and other barriers to oral administration30. In these systems, a drug is encapsulated
in a biocompatible, biodegradable polymer that breaks down in the body, and the drug is
released in a controlled manner31. At the time of their development, long-term (months to
years) controlled release of drugs was out of reach, and these particles were some of the
first to show that it was possible32. Since then, the drug delivery field has exploded with
interest in polymer particles, and new formulations and methods of fabrication are
developed every year33. The global advanced drug delivery systems market was estimated
to be $178 billion as of 2015 and estimated to grow to $227 billion as of 202034. Interest in
these systems is expected to grow further, as the population ages and new treatment
technologies are needed every year. This platform has proven itself useful and clinically
relevant. The work presented in this dissertation focuses on delivery of resveratrol and
mannose for therapeutic applications such as obesity and muscle atrophy, along with some
innovations to polymer microparticle morphology and functionality.
Poly lactic acid (PLA) and poly glycolic acid (PGA) were some of the most
successful and early polymers to be used as polymer microparticle delivery vehicles35,36.
These polymers had found earlier uses as resorbable medical devices such as sutures, stents
and structural meshes37. As a result, some groups repurposed them as drug delivery
vehicles38. PLA, PGA and their copolymer poly(lactide-co-glycolide) PLG were found to
be biocompatible and could degrade in water, allowing them to be used when a biomaterial
is needed for a period of time, but after a while could be resorbed by the body and not
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require surgical removal39. These, and other polyesters, degrade via hydrolysis of the ester
bond, and their degradation patterns have been well established40–42. PLG microparticle
formulations for drug delivery advanced to clinical trials during the 1980s, and Lupron
Depot was FDA approved in 198943. Since then, around 20 PLG-based microparticle
formulations have achieved FDA approval44. Although 20 PLG-based formulations is
impressive, one review article suggests this number should be much higher, as there are
many more than 20 drugs that could benefit from PLG encapsulation44. Although
encapsulation of drugs in polymer particles is a fairly simple concept, producing
microparticles with desired effects is challenging45–47.
Many particle characteristics need to be considered and controlled in order to make
reproducible and optimized particles. For example, previous work has shown that particle
size48, particle shape49, polymer composition41, molecular weight42, degradation rate39 and
drug release rate50 are all very important response variables in particle production. To
achieve control over these response variables, parameters of fabrication techniques need to
be tuned in precise ways. Many efforts have been made to improve control of many of
these variables, such as size and drug release, where complicated fabrication methods were
required for precise control46,51.
1.4 Oil in Water (O/W) emulsion solvent extraction method
There are many ways to fabricate polymer microparticles for drug delivery, such as
emulsion-based formation, spray drying, phase separation and solvent casting52,53. Among
these, the O/W emulsion solvent extraction/evaporation method is the most commonly
used for drugs with low water solubility45,54,55. The O/W emulsion solvent
extraction/evaporation method involves dissolving the polymer in an organic solvent
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(dispersed phase) and an emulsifier in water (continuous phase). These two phases are
homogenized at high speed and a primary emulsion is formed. This emulsion is added to
the aqueous phase, which extracts the organic solvent and, in some cases, promotes
evaporation of the organic solvent. This causes the polymer to precipitate into
microparticles, stabilized by an emulsifier. These particles can then be lyophilized into a
powder and stored in dry conditions for long periods (months to years) before delivery.
FDA-approved particles such as Vivitrol and Lupron Depot use this fabrication method for
injectable microparticles for systemic delivery of agents56,57. As a result, this method has a
track record of FDA approval, and new concepts for particle design could build off the
O/W emulsion solvent extraction technique and receive a smoother approval process.
Many drugs have been encapsulated with this method in the literature54,58, but there are still
many drugs that have not been studied.
1.5 Opportunities for innovation on biodegradable polymer microparticles
Although biodegradable polymer particles were initially conceived as drug delivery
vehicles, they can be useful for other purposes as well. They can be used as supports for
presenting bioactive agents or ligands to the surface of cells59 and have also been used as
novel vaccine carriers31,60. In this dissertation, the focus will be on their usefulness as drug
delivery vehicles and as supports for ligand-receptor interactions. Morphology and surface
functionality are two parameters of polymer particles that have been shown to be of
importance to the cell-material interaction of particles in the body. Morphology and surface
functionality are also addressed closely in this dissertation.
Morphology of particles can affect the host response to biomaterials61. Despite this,
relatively few studies fabricating PLG particles have taken into account the effect of the
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morphology of the particles on biological responses49,62. The default morphology of a
polymer particle is a smooth sphere due to the way the particle is formed in the O/W
emulsion system. In an emulsion, a sphere is the shape that is thermodynamically favorable
and other shapes are difficult to achieve without disrupting the stability of the emulsion63.
Some other methods have been employed to produce particles of varying morphologies.
Flow lithography was used to produce particles with wrinkled morphology, and these
particles were tested in vitro for their interaction with cells. It was found the wrinkled
particles interacted more readily than spherical particles64. This suggests that morphology
is a key parameter of interest in particle-cell interactions.
Surface functionality is also an aspect of polymer particles that has a large effect
on cell-material interactions. Efforts to modify the surface of PLG particles came about not
long after the first PLG particles were designed65. Attaching surface ligands to PLG
particles was proposed as a way to target cells of interest or even to promote cellular
signaling through receptor activation66. Most methods for surface ligand attachment
require many steps and harsh chemicals. Methods that involve one-step reactions and
milder chemistry may result in more readily FDA approved formulations.
Taken together, there are many areas in the field of polymer microparticle
formation to be optimized, including testing new drugs such as resveratrol for their effect
on adipose tissue, and importance of developing methods to tune morphology and surface
functionality using components in FDA approved systems.
1.5.1 Aim 1: Develop microparticles for resveratrol delivery to adipose tissue
Previous groups have encapsulated resveratrol to improve bioavailability28,67, but
none have, to our knowledge, considered delivering resveratrol in microparticles to the
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adipose tissue. We propose that PLG particle delivery of resveratrol to the adipose tissue
could improve the bioavailability, and that these particles can be easily tuned for size using
parameters of the oil in water emulsion solvent extraction method. Our hypothesis was that
PLG microparticles could be loaded with resveratrol to a high extent, and that the
resveratrol would be bioactive and cause delipidation in adipocytes. In this aim we find
that not only can resveratrol be loaded into PLG particles to a high extent, it is also
bioactive in that it causes lipid mobilization in adipocytes grown in culture. We also show
that resveratrol causes morphology changes in PLG particles dependent on resveratrol and
emulsifier concentration68.
1.5.2 Aim 2: Understand the impact of resveratrol on morphology of PLG particles
In this aim our objective was to study the effect on morphology of PLG particles
using resveratrol as a secondary emulsifier. We find that adding resveratrol to O/W
emulsions affects the morphology of PLG particles68. Morphology is a poorly studied but,
by all accounts, impactful aspect of particle-based drug delivery to cells and tissue49,69.
Particles have been shown to adhere more readily to wrinkled particles64. Particles with
distinct morphologies are shown to elicit different immune responses70. In this aim we
show that resveratrol causes distinct effects on the morphology of PLG particles after being
added to the emulsion, and that this is cosolvent and resveratrol concentration dependent71.
1.6 Using modified PVA for surface functionalization of PLG particles for
macrophage targeting
Many methods for functionalizing the surface of PLG particles have been studied
in the literature72,73. Simple adsorption processes for attaching ligands have been used, as
well as complex chemistries. Most chemical modifications involve modifying PLG after
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particle fabrication. Utilizing the concept of PVA adsorption on the surface of PLG
microparticles74, we sought to chemically modify PVA, and use modified PVA in the PLG
particles fabrication process. A major benefit of this process is that characterization of the
product is simpler, as characterization occurs prior to forming the particle.
1.6.1 Aim 3: Designing functionalized PLG particles to induce anti-inflammation in
macrophages for treatment of muscle atrophy
Mannose is a ligand for mannose receptor in macrophages that has potential use as
a targeting moiety in polymer particles75 and that can also cause cell-signaling events76. In
fact, many groups have used mannose as a surface functionalizing group to target and
signal to macrophages in vitro and in vivo77–80. We proposed that modifying PVA for
functionalizing PLG particles would be a simpler and milder approach for surface
presentation of ligands such as mannose.
We hypothesize that PLG particles can be functionalized using mannose modified
PVA to induce anti-inflammation for treatment of muscle atrophy. In this aim we show
that PLG particles can be successfully functionalized with modified PVA via NMR
analysis and confocal microscopy. We also show that mannose attached to PLG particles
is functional and that it induces mannose receptor colocalization. In addition, media
conditioned with macrophages treated with mannose functionalized particles induced
myotube fusion in vitro. The work in this aim demonstrates the potential in PVA
modification for surface functionalizing PLG particles and mannose receptor activation
as a potential treatment option for muscle atrophy.
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CHAPTER 2
DEVELOPMENT OF MICROPARTICLES FOR CONTROLLED
RELEASE OF RESVERATROL TO ADIPOSE TISSUE AND THE
IMPACT OF DRUG LOADING ON PARTICLE MORPHOLOGY AND
DRUG RELEASE1

2.1 Introduction
Resveratrol is a polyphenolic compound occurring in various plants, including
grapes, berries, and peanuts22, as a defense mechanism against environmental stresses such
as infections and ultraviolet radiation81. A remarkable range of biological functions are
attributed to this molecule. For example, it acts as a cancer prevention agent 82, an antiinflammatory83, and an antioxidant84. More recently, it has been identified as an antiobesity compound26,85. It exerts this effect by activating signaling pathways in fat cells that
are also activated by energy restriction (i.e. dieting)26. The result is an increase in lipolysis
and fatty acid oxidation that leads to a reduction in body fat86. Unfortunately, resveratrol
suffers from poor bioavailability, requiring large and frequent doses, thereby hampering its
vast therapeutic potential29,87.

1

Isely, C., Hendley, M.A., Murphy, K.P., Kader, S., Annamalai, P., Jabbari, E., and
Gower, R.M. 2019. International Journal of Pharmaceutics. 568: 118469. Reprinted here
with permission of publisher.
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Resveratrol is generally administered orally, but extensive first pass metabolism
results in the molecule’s low concentration in the systemic circulation and accumulation in
tissues88. To address this issue, we are developing biodegradable microparticles as drug
depots for controlled release of resveratrol within fat tissue. Goals for this study were
maximizing drug loading to decrease the mass of carrier delivered, limiting particle size to
a range above 5 microns to inhibit phagocytic clearance, and producing drug release
profiles with a duration expected to sustain resveratrol at levels observed in the adipose
tissue in rats fed a diet laced with resveratrol89. While microcarriers have been investigated
for controlled release of resveratrol previously, they were designed to release resveratrol
quickly to the gut90, skin91, or nasal mucosa92. In those previous studies, total drug release
occurs in hours to days, which is too short for our applications. In effort to extend release
duration, we have selected a relatively high molecular weight poly(lactide-co-glycolide)
copolymer that is 75% lactide as the drug carrier. We have extensive experience with this
polymer formulation and know that it integrates well with the adipose tissue93–95. Single
emulsion/solvent evaporation was utilized to encapsulate resveratrol within the polymer
matrix.
Herein, we describe surprising effects of resveratrol on particle morphology and
demonstrate how resveratrol loading and release can be controlled by changing particle
size. Finally, we report a simple approach, with mild chemistry, to functionalize poly(vinyl
alcohol) with fluorescein, which enabled visualization of resveratrol’s impact on particle
surface chemistry.
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2.2 Materials and Methods
2.2.1 Materials
75:25 poly (D,L-lactide-co-glycolide) with a lauryl ester end group and an inherent
viscosity of 0.79 dL/g was purchased from Evonik. Dichloromethane, resveratrol, poly
(vinyl alcohol) (Mw 13,000-23,000, 87-89% hydrolyzed), and fluorescein isothiocyanate
were purchased from Sigma (St. Louis, MO). 200 proof ethanol was purchased from Decon
Laboratories (King of Prussia, PA). Dimethyl sulfoxide (DMSO) was purchased from
Fisher (Hampton, NH). Ultrapure water was obtained from a Thermo Scientific Barnstead
Nanopure system. 3T3-L1 mouse embryonic fibroblasts (CL-173) were purchased from
ATCC (Manassas, VA). Dulbecco’s Modified Eagle’s Medium (DMEM) with 4.5 g/L
glucose and L-glutamine was purchased from Corning Cellgro (Corning, NY). Trypsin
with 0.25% EDTA, Fetal Bovine Serum (FBS) and Pen/Strep were purchased from Fisher
(Hampton, NH). Super Calf Serum was purchased from GemCell (Sacramento, CA).
Insulin (bovine), dexamethasone, and methylisobutylxanthine (IBMX) were purchased
from Sigma (St. Louis, MO).
2.2.2 Resveratrol Loaded PLG Particle Fabrication
Poly(lactide-co-glycolide) (PLG) particles were prepared using a single oil-inwater emulsification/solvent evaporation method as described previously with
modifications95. Briefly, PLG was dissolved in dichloromethane (DCM) at 6%
(weight/weight, hereafter labeled as 6%) and resveratrol (Sigma) was dissolved in 100%
ethanol at 40 mg/mL. The organic phase, which consisted of varying volume ratios of
ethanol and DCM, was added to an aqueous solution of polyvinyl alcohol (PVA) at 1 or
2% (weight/volume, hereafter labeled as 1 or 2%) in a 1:7 volume ratio and homogenized
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using a Kinematica PT3100D homogenizer. The emulsion was then added to an aqueous
solution of PVA and stirred for 5 hours, allowing the DCM and ethanol to evaporate and
the particles to harden. The volume of PVA solution in the solvent evaporation beaker was
5 times greater than the emulsion mixture. The particles were then passed through a 40 µm
filter, collected via centrifugation, and washed 4 times in ultrapure water. Particles were
frozen at -20°C and lyophilized overnight. Particles were then stored protected from light,
under vacuum, at room temperature.
2.2.3 Scanning Electron Microscopy and Light Microscopy
Carbon adhesive tape was attached to aluminum SEM stubs and particles were
spread onto the stubs. Compressed air was applied briefly to the particles to create a
monolayer on the carbon tape. Particles were sputtered with gold 3 times for 60 seconds in
a Denton Desk II Vacuum sputter coater. Images were taken using a TESCAN Vega3
Scanning Electron Microscope at 10kV.
Light microscopy images were taken on an EVOS FL microscope at 20x. Particles
were prepared in ultrapure water and suspended at a concentration of 0.25 mg/mL. 400 µL
of these suspensions was added to a 48-well plate and allowed to settle prior to image
acquisition.
2.2.4 Measurement of Particle Size Distribution
Particle size distribution for each batch of particles was determined by analyzing
light microscopy images with ImageJ software. Briefly, three representative images were
acquired and converted to binary. The ImageJ Particle Analysis plugin-in was used to
measure particle diameter. The size data was then plotted as a histogram with a 5 µm binwidth. We report the mean particle diameter and the coefficient of variation (CV%), which
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is the standard deviation divided by the mean. We validated our image analysis method
with dynamic light scattering (Figure 2.12) and with monodispersed polystyrene particles
that were obtained from Duke Standards (Figure 2.13).
2.2.5 Mass Yield, Resveratrol Loading, and Encapsulation Efficiency
Particle mass yield was calculated according to equation 1.
𝑀𝑎𝑠𝑠 𝑌𝑖𝑒𝑙𝑑 (%) = (𝑀

𝑀𝑃𝑇

𝑃𝐿𝐺 +𝑀𝑅𝐸

) ∗ 100

(1)

Where MPT is the mass of particles recovered from the emulsion, MPLG is the mass of PLG
added to the emulsion, and MRE is the mass of resveratrol added to the emulsion.
Resveratrol loading was determined via UV-Vis by dissolving resveratrol particles
in DMSO and measuring absorbance at 330 nm using a Spectramax 190 UV-Vis
spectrophotometer. A 10-point standard curve was prepared by dissolving 1 mg of empty
particles and a known mass of resveratrol in DMSO. Figure 2.14 depicts a typical standard
curve. Resveratrol concentration was determined by comparing the unknown samples to
the standard curve. Resveratrol loading was calculated by equation 2.
𝜇𝑔

𝑀

𝐿𝑜𝑎𝑑𝑖𝑛𝑔 (𝑚𝑔) = 𝑀𝑅
𝑃

(2)

Where MP is the mass of particles dissolved in DMSO and MR is the mass of resveratrol
measured in those particles.
Efficiency of resveratrol loading into the particles was calculated by first
calculating the theoretical amount of resveratrol loaded into an entire batch of particles
(particle loading multiplied by the mass of particles recovered from the emulsion) and then
dividing that number by the amount of resveratrol added to the emulsion as depicted in
equation 3.
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𝐿𝑜𝑎𝑑𝑖𝑛𝑔∗𝑀𝑃𝑇

𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 (%) = (

𝑀𝑅𝐸

) ∗ 100

(3)

Where Loading is calculated by equation 2, MPT is the mass of particles recovered from the
emulsion, and MRE is the mass of resveratrol added to the emulsion.
Resveratrol loading was also determined via HPLC. Particles were dissolved in
DMSO and then precipitated by adding methanol, water and acetic acid while retaining
soluble resveratrol. The final concentrations were 10% DMSO, 30% Methanol, 57.5%
Water, and 2.5% Acetic Acid. After the PLG precipitated, the mixture was centrifuged at
1750xg for 10 min and the supernatant was collected for HPLC analysis. Free resveratrol
was prepared in a solution of the same concentration of solvents to make a 6-point standard
curve.
A Thermo Ultimate 3000 binary gradient system was used for HPLC analysis. A
Chromegabond WR C18 column was used in the analysis and the flow rate was kept at 0.2
mL/min. An Agilent G1315B Diode Array UV Detector was used in the analysis at 306nm.
Solvent A was water and Solvent B was acetonitrile. From 0-30min the solvent was 90%
A and 10% B, from 30min to 31min the solvent was 5% A and 95% B, and from 31min on
the solvent was 90% A and 10% B. The area under the curve of the chromatograms of free
drug was plotted against concentration to make a standard curve shown in Figure 2.16. The
amount of resveratrol in particles was calculated by interpolating this curve. Loading was
calculated using Eq. 2.
2.2.6 In Vitro Release Assay
Particles containing resveratrol were dispersed in 1 mL ultrapure water in 1.5 mL
tubes and shaken at 650 rpm using an Eppendorf Thermomixer R maintained at 37°C. At
the designated time point, the particles were collected via centrifugation, suspended in
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ultrapure water, and centrifuged again. The particles were then frozen and lyophilized.
Particles were analyzed for resveratrol loading as described in section 2.5. Resveratrol
released (%) was calculated by equation 4.
𝐿0 −𝐿𝑡

𝐷𝑟𝑢𝑔 𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑 (%) = (

𝐿0

) ∗ 100

(4)

Where L0 is the initial loading of the particles, and Lt is the loading at time t during the
release assay.
2.2.7 Ethanol Wash of Resveratrol Particles
Particles were suspended in 100% ethanol for 1 minute. The particles were then
collected via centrifugation, suspended in ultrapure water, frozen, and lyophilized.
Particles were analyzed for resveratrol loading as in section 2.5. The amount of resveratrol
removed by the ethanol wash was calculated by equation 5.
𝐷𝑟𝑢𝑔 𝑟𝑒𝑚𝑜𝑣𝑒𝑑 (%) = (

𝐿0 −𝐿𝐸𝑡𝑂𝐻
𝐿0

) ∗ 100

(5)

Where L0 is the initial loading and LEtOH is the loading after the ethanol wash.
2.2.8 3T3-L1 Adipocyte Cell Culture
3T3-L1 fibroblasts (ATCC), were differentiated into adipocytes following ATCC’s
protocol, with slight modifications. Briefly, 3T3-L1 cells were seeded in 6 well plates at
80,000 cells/well and cultured in DMEM supplemented with 10% Super Calf Serum and
1% Pen/Strep. 48 hours after confluence was reached, media was exchanged with
“differentiation media” consisting of DMEM supplemented with 10% FBS, 10 µg/mL
bovine insulin, 0.25 µM dexamethasone, and 0.5 mM IBMX. 48 hours after differentiation
media was added, media was exchanged for DMEM supplemented with 10% FBS and 10
µg/mL bovine insulin. After another 48 hours, media was exchanged for DMEM
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supplemented with 10% FBS. Cells were then cultured until treatment with particles, which
occurred 9 days after exposure to the differentiation media.
2.2.9 Particle Treatment and Oil Red O Assay
Blank PLG particles (300 µg/mL), resveratrol loaded PLG particles (300 µg/mL),
or free resveratrol (60 µM) was added to 3T3-L1 adipocytes 9 days after exposure to the
differentiation media. 48 hours later cells were washed, fixed in 10% formalin and stained
with Oil Red O as follows. Cells were washed with ultrapure water and then washed with
60% isopropanol for 2 minutes. Cells were then incubated with Oil Red O for 10 minutes
at room temperature. Cells were then washed four times with ultrapure water. Images were
taken on a Nikon Eclipse Ci microscope using the 4x objective. Oil Red O was extracted
from the wells by incubating the cells in 100% isopropanol for 10 minutes at room
temperature. Absorbance of extracted Oil Red O was measured at 500 nm using a
spectrophotometer.
2.2.10 FITC Labeling of PVA and Particle Fabrication
PVA was dissolved in DMSO at 50 mg/mL. FITC and dry KOH were added to the
solution at concentrations of 3.5 mg/mL and 0.5 mg/mL, respectively. This solution was
stirred at room temperature for 5 hours. The solution was then dialyzed using dialysis
tubing (3.5 kDa MWCO) in 3 L of ultrapure water for 3 days, replacing the water twice
daily. The FITC labeled PVA (FITC-PVA) was collected, frozen, and lyophilized. This
FITC-PVA was then used to fabricate PLG particles as described above.
2.2.11 Confocal Microscopy
Particles were suspended in a 50:50 mixture of ultrapure water and anti-fade
mounting media, pipetted on a slide, mounted with a coverslip, and dried overnight. Images
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were acquired on a Zeiss 700 confocal microscope using the 488nm laser. Particles were
analyzed for fluorescence intensity using ImageJ as follows. A line was drawn through
each particle and the maximum intensity of FITC on the surface was recorded using the
plot profile function. 27 particles were analyzed for each condition. Data is mean ± standard
deviation of the measured surface pixel intensity.
2.2.12 Flow Cytometry
Particles were suspended in ultrapure water and analyzed with a BD FACS Aria
flow cytometer for FITC fluorescent intensity. Approximately 600 particles were analyzed
for each condition. Data was analyzed using FlowJo (Treestar).
2.2.13 Statistical Analysis
Statistical analysis was carried out using GraphPad Prism. Where appropriate, an
unpaired t-test or one-way ANOVA followed by Tukey’s multiple comparison test were
carried out to compare differences between means. Error bars represent the standard
deviation of the means. Linear trends were determined with a Pearson’s correlation test.
Specific details regarding statistical analyses carried out for each data set are described in
the figure legend.
2.3 Results
2.3.1. The Effect of Ethanol on PLG Particle Fabrication
We sought to produce PLG particles containing resveratrol using a single
emulsion/solvent evaporation technique in which the oil phase is PLG dissolved in DCM
and the aqueous phase is water containing PVA as the emulsifier. However, resveratrol is
not soluble in DCM and it is well established maximal encapsulation is achieved when the
drug is soluble in the oil phase54. Resveratrol is soluble in ethanol up to 50 mg/mL96 and
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thus, we investigated ethanol as a co-solvent to increase resveratrol’s solubility in the oil
phase.
Ethanol reduces the interfacial tension between water and DCM97, which favors the
formation of smaller droplets during emulsification98. Therefore, we first determined
ethanol’s effect on particle size and mass yield in the absence of resveratrol. 6% PLG was
poorly soluble in a 1:1 mixture of ethanol and DCM (Figure 2.1A) and few particles formed
during the emulsion process, with a mass yield of 11±4 % (Figure 2.1B). In contrast, 6%
PLG was soluble in a 1:2 or a 1:3 mixture of ethanol and DCM (Figure 2.1A), and particle
mass yield was similar between the two conditions, 63±3 % for 1:2 versus 67±7 % for 1:3
(Figure. 2.1B). Furthermore, both conditions showed similar mass yield compared to DCM
alone (Figure 2.1B). Representative light microscopy images of the 1:2 and 1:3
formulations are shown in Figure 2.1C and D. We found that 1:2 particles were smaller
than the 1:3 particles with an average diameter of 5.7 µm versus 10.5 µm (Figure 2.1E and
F). In addition, the 1:3 particles had a similar size distribution to those made with DCM
alone (data not shown). Thus, we selected a 1:3 volume ratio of ethanol and DCM as the
oil phase in subsequent experiments.
2.3.2 Fabrication of Resveratrol Loaded PLG Particles
We next employed the single emulsion solvent/evaporation method to fabricate
resveratrol loaded PLG particles (from here on in this chapter referred to as resveratrol
particles). We found that a 40 mg/mL solution of resveratrol in ethanol was miscible with
an 8 % solution of PLG in DCM when mixed at a 1:3 ratio and no precipitates formed (data
not shown).
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Figure. 2.1. The effect of ethanol on particle mass yield and size. (A)
Vials containing 1:1, 1:2, and 1:3 volume ratios of ethanol and DCM with
6% PLG. (B) Mass yield of particles made with an organic phase consisting
of 1:1, 1:2, 1:3 volume ratios of ethanol and DCM and DCM only. Data is
the mean of three independent particle fabrications and analyzed with oneway ANOVA followed by Tukey’s multiple comparisons test. ****
p<0.0001. (C, D) Light microscopy images and (E, F) size distribution of
particles made with 1:2 and 1:3 mixtures of ethanol and DCM. Scale bar
indicates 40 µm.
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We utilized this mixture for the oil phase of the emulsion, which thus contained
resveratrol at 10 mg/mL and 6% PLG. This oil phase yielded particles that were irregularly
shaped with ruffled surfaces (Figure 2.2A) compared to particles made with an oil phase
that consisted of only DCM and 6% PLG (Figure 2.2C). Particles made using a 1:3 mixture
of ethanol and DCM that lacked resveratrol were also smooth and spherical (Figure 2.2B),
indicating resveratrol is responsible for the altered particle morphology. It was determined
that lyophilization was not a factor in the irregular morphology through imaging resveratrol
particles before and after lyophilization, seen in Figure 2.15. Loading was 65±5 µg/mg for
the resveratrol particles and mass yield was 40±5 %, which is lower than the mass yield
for the other two conditions, depicted in Figure 2.1B. Furthermore, resveratrol loading
measured using UV-Vis was verified using HPLC. HPLC analysis yielded a particle
loading of 69±7 µg/mg, which was consistent with loading found using the UV-Vis
method. Therefore, UV-Vis, a simpler and more cost-effective method, was used for the
remainder of the study. The HPLC standard curve is shown in Figure 2.16. Taken together,
the data indicates that resveratrol can be loaded into PLG particles using the single
emulsion/solvent evaporation technique, but mass yield is decreased, and morphology is
altered.
In addition, it is important to note that all particles fabricated using this method
resulted in flowable powders, suggesting no aggregation. Images of particles before and
after spinning the tube show that particles flow and take the shape of the container, seen in
Figure 2.17.
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Figure 2.2. Morphology of resveratrol loaded PLG particles. Representative images
of particles made with an oil phase consisting of (A) a 1:3 mixture of ethanol and DCM
and 10 mg/mL of resveratrol, (B) a 1:3 mixture of ethanol and DCM and no resveratrol,
and (C) DCM with no resveratrol or ethanol. All particles were made with an oil phase
that was 6% PLG. The aqueous phase of the emulsion contained 1% polyvinyl alcohol.
Scale bars indicate 50 µm.
3.3 Bioactivity of Resveratrol Loaded into PLG Particles
Having successfully loaded PLG particles with resveratrol, we determined if
resveratrol remained bioactive following the fabrication process. To accomplish this, we
investigated the ability of the resveratrol particles to induce lipolysis in differentiated 3T3L1 adipocytes by measuring lipid content with an Oil Red O assay. 3T3-L1 adipocytes are
differentiated from 3T3-L1 fibroblasts and extensively used to model human adipocytes.
Resveratrol promotes lipolysis in these cells25,27, which decreases intracellular lipid
content. Lipid content can be visualized with Oil Red O, a lipophilic dye, (Figure 2.3A-F)
and lipid content can be quantified by extracting the dye (Figure 2.3G) and measuring the
solution’s absorbance (Figure 2.3H). While the undifferentiated fibroblasts do not stain
strongly with Oil Red O due to a low level of intracellular lipid (Figure 2.3A), 3T3-L1
adipocytes exhibit extensive staining throughout the monolayer (Figure 2.4B). We found
that treatment of adipocytes with 300 µg/mL of resveratrol particles decreased Oil Red O
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staining to a similar level of cells treated with 60 µM resveratrol (Figure 2.3D versus 2.3E
and 2.3H). As controls, adipocytes were treated with particles that did not contain
resveratrol (Figure 2.3C) and ethanol, which is a vehicle control for the resveratrol
treatment (Figure 2.3F). Importantly, these treatments did not decrease Oil Red O signal.
Taken together these data indicate that the resveratrol remains bioactive following its
incorporation into PLG particles.
2.3.4. In Vitro Release Profile of Resveratrol Particles
Having determined that the resveratrol remains bioactive once loaded into PLG
particles, we next investigated the release kinetics of resveratrol from the particles in vitro.
Particles were mixed in water for 6 weeks (Figure 2.4A). Release at early time points (0.25,
1, and 3 days) was highly variable with coefficients of variation in excess of 80% at day 3.
The first 14 days of the release assay was repeated once more, however large variability in
release was still observed (Figure 2.4B). We hypothesized that irregular morphology was
responsible for the release profile’s high variability and set out to produce resveratrol
particles with smooth surfaces and spherical geometry in effort to decrease variability in
drug release.
2.3.5. The Effect of PVA and Resveratrol on Particle Morphology
Our SEM data (Figure 2.5) indicated that incorporation of resveratrol into the PLG
particle was altering surface morphology. We speculated that resveratrol was interfering
with PVA’s ability to function as an emulsifier and this could lead to the ruffled surface.
Since the amount of PVA on the surface of a PLG particle can be increased by increasing
the PVA concentration in the aqueous phase99, we investigated if increasing the
concentration of PVA in the emulsion and solvent evaporation steps would lead to smooth,
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Figure 2.3. The effect of resveratrol loaded particles on adipocyte lipid
content. (A-F) Images of cell monolayers stained with Oil Red O. Experimental
groups include (A) undifferentiated fibroblasts, (B) adipocytes with no treatment,
(C) adipocytes treated with 300 µg/mL of PLG particles, (D) adipocytes treated
with 300 µg/mL of resveratrol particles (E) adipocytes treated with 60 µM
resveratrol dissolved in ethanol and suspended in DMEM at 0.05 v/v %, and (F)
adipocytes treated with an equivalent amount of ethanol. (G) Image of Oil Red O
extracted in isopropanol from the six experimental groups. (H) Absorbance
values of Oil Red O extracted from cells using isopropanol at 500 nm. Absorbance
correlates to lipid content inside the cells. Labels for (H) correspond to (C-E) in
terms of treatment group. The experiment was repeated 4 times. One-way
ANOVA was conducted followed by a Tukey multiple comparison test. * p<0.05.
Scale bars indicate 500 µm.
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Figure 2.4. In vitro release profiles of resveratrol particles. (A) Six-week
resveratrol release profile. Data are mean ± standard deviation from one experiment
with three replicates per time point. (B) Two-week resveratrol release profile. Data is
plotted as mean ± standard deviation from two independent experiments with three
replicates per time point.
spherical particles. We found that doubling the PVA concentration in the emulsion step
(from 1 to 2%) and increasing PVA in the solvent evaporation step (from 0 to 1%) did not
improve particle morphology (Figure 2.5A). In fact, we increased the concentration of PVA
in the emulsion step to 5%, but the particles still exhibited irregular morphology (Figure
2.18). As an alternative approach, we incrementally decreased the concentration of
resveratrol in the oil phase from 10 mg/mL to 4 mg/mL by changing the volume ratio of
the ethanol solution (containing 40 mg/mL resveratrol) and DCM from 1:3 to 1:9. A stark
change in morphology was observed when the resveratrol concentration decreased from 5
mg/mL to 4 mg/mL, with the latter yielding spherical particles with smooth surfaces
(Figure 2.5).
Having determined conditions that yield smooth, spherical particles, we
investigated the impact of PVA concentration, in both the emulsion and solvent
evaporation steps, on morphology. We found that a PVA concentration of 2% in the
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emulsion step and 1% in the solvent evaporation was necessary to maintain the smooth,
spherical morphology as decreasing PVA in either step led to irregular morphology (Figure
2.6). Furthermore, we found that resveratrol loading nearly doubled (from 5.3 to 9.6
µg/mg) as we decreased PVA concentration from 2% to 1% in the emulsion step and from
1% to 0% in the evaporation step. Taken together, the data suggest that PVA and resveratrol
compete for incorporation into the particle and when present at high enough levels,
resveratrol alters particle morphology.

Figure 2.5. The effect of resveratrol concentration on particle morphology. (A-D)
Images of resveratrol loaded particles made with decreasing concentrations of
resveratrol in the oil phase (shown in parentheses), which was achieved by decreasing
the volume ratio of ethanol to DCM, which is depicted as ETOH:DCM ratio above
each image. 6% PLG was used in the emulsion. The PVA concentration was 2% in the
emulsion step and 1% in the evaporation step. Scale bars indicate 50 µm.
2.3.6. The Effect of Resveratrol on the Particle’s PVA Content
To further investigate if resveratrol was interfering with PVA’s ability to associate
with the particle’s surface, we measured how PVA content and distribution changes with
resveratrol loading by utilizing FITC-labeled PVA (FITC-PVA). Confocal microscopy of
spherical particles indicated that FITC-PVA was present on the surface of the particle and
evenly distributed (Figure 2.7 A-C). This was the case whether or not resveratrol was
incorporated into the particle as long as the spherical morphology was preserved; however,
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Figure 2.6. The effect of PVA concentration on particle morphology. (A-D)
Images of resveratrol particles made with an oil phase consisting of a 1:9 mixture of
ethanol to DCM and containing 4 mg/mL resveratrol and 6% PLG. PVA
concentrations in the emulsion step and solvent evaporation step are indicated above
the image as emulsion % (w/v) and evaporation % (w/v), respectively. Scale bars
indicate 50 µm. Loading values were as follows: 5.3 µg/mg (A) 5.4 µg/mg (B) 7.1
µg/mg (C) 9.6 µg/mg (D).
particles made with a high resveratrol loading (65 µg/mg), which leads to the ruffled
surface morphology, exhibited an altered FITC signal that suggested PVA was not evenly
distributed over the particle’s surface (Figure 2.7D). While not strongly apparent in the
confocal images by eye, image analysis revealed that the FITC signal at the surface of the
spherical particles was decreased when resveratrol was encapsulated into the particle
(Figure 2.7E). To confirm the confocal data, we conducted flow cytometry of the particles
made with FITC-PVA (Figure 2.8). Congruent with the confocal data, the FITC signal is
decreased on resveratrol particles. Taken together, the data suggests that resveratrol
incorporation into the particle decreases the amount of PVA that associates with the
particle’s surface, suggesting that resveratrol accumulates at the particle surface.
2.3.7. The Effect of Particle Size on Resveratrol Loading
Based on our findings up to this point, we suspected some fraction of the resveratrol
incorporated into a particle was loaded on its surface. If this was the case, particle size
would impact resveratrol loading because specific surface area increases as particle size
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Figure 2.7. Confocal imaging of particles made with FITC-PVA. Fluorescent
images of particles made with oil phases consisting of 6% PLG in (A) DCM (B) 1:9
ethanol:DCM, (C) 1:9 ethanol:DCM containing 4 mg/mL resveratrol, and (D) 1:3
ethanol:DCM containing 10 mg/mL resveratrol. FITC signal intensity was quantified
using ImageJ and is depicted in panel (E) as mean ± standard deviation for 27 particles
per group. Scale bar is 20 µm.
decreases. To investigate the effect of particle size on resveratrol loading, we produced
particles with diameters ranging from 5 to 13 µm by changing the emulsion’s
homogenization time and speed. We found that increasing homogenization time narrowed
the size distribution and increasing homogenization speed decreased particle size, but all
particles exhibited spherical morphologies (Figure 2.9). After producing several additional
batches of particles, we determined that 11,000 RPM for 5 minutes was best for producing
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Figure 2.8. Flow cytometry of resveratrol particles made with FITC-PVA. (A)
Histograms depicting FITC fluorescence intensity of particles made with oil phases
consisting of 6% PLG in DCM (blue), 1:9 ethanol:DCM (red), and 1:9 ethanol:DCM
containing 4 mg/mL resveratrol (green). (B) Mean fluorescence intensity (MFI) and
standard deviation of data from panel (A). 600 particles were analyzed for each group.

smaller particles, which had a diameter of 5.2±0.9 µm and a loading of 4.9±0.4 µg/mg,
while 7,000 RPM for 30 seconds was best for producing larger particles, which had a
diameter of 10.3±1.9 µm and a loading of 2.5±1.2 µg/mg (Figure 2.10A, blue dots and red
dots). Congruent with the idea that some of the resveratrol is surface loaded, there was a
negative correlation between resveratrol loading and particle diameter (Figure 2.10A).
Also, because there is no impact of particle size on mass yield, drug encapsulation
efficiency also increased with decreased particle diameter (Figure 2.10 B and C).
2.3.8. The Effect of Particle Size on Resveratrol Release
Having established that particle size impacts resveratrol loading, we next
investigated the effect of particle size on resveratrol release. We found that 4 µm particles
with a drug loading of 4.7 µg/mg exhibited a different release profile compared to 11 µm
particles with a drug loading 2.5 µg/mg (Figure 2.11). Specifically, 4 µm particles released
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Figure 2.9. The effect of homogenization time and speed on particle size. Images
and size distributions for particles homogenized at 7000 rpm for increasing amounts
of time (A-D) and homogenized for 5 minutes at increasing homogenization speeds
(E-H). Particles were produced with a 1:9 mixture of ethanol to DCM containing 4
mg/mL resveratrol. The PVA concentration is 2% in the emulsion step and 1% in the
evaporation step. Scale bars indicate 20 µm. x bar is mean ± standard deviation. CV
is coefficient of variation. RPM is rotations per minute and indicates the speed of the
homogenizer tip.

60% of their resveratrol in the first 24 hours, after which time no more resveratrol was
released, but resveratrol still remained in the particles (Figure 2.11A). In contrast, 11 µm
particles released 20% of their resveratrol in the first 24 hours and then continued to release

30

Figure 2.10. Effect of particle diameter on drug loading and particle mass yield.
Plots of particle diameter versus (A) drug loading, (B) drug encapsulation efficiency,
and (C) particle mass yield for several batches of particles. Pearson correlation
coefficients and associated P values were calculated to determine the extent of a linear
correlation between variables.
drug for 14 days. In addition, the 11 µm particles exhibited lower variation in the amount
of drug released at early time points compared to the 4 µm particles.
Following the release assay, we suspected the burst release exhibited by the 4 µm
particles was due to resveratrol associated with the surface of the particle, which requires
24 hours to be released, possibly due to its poor solubility in water. To investigate this, we
washed particles in 100% ethanol for one minute and then measured the residual resveratrol
loading. We found that the ethanol wash removed approximately the same amount of
resveratrol as was released during the first 24 hours of the release assay for large (9 and 11
µm) and small (4 and 5 µm) particles (Figure 2.11A versus 2.11B). Importantly,
submerging the 9 or 5 µm particles in water for one minute did not remove any resveratrol
(data not shown). While it would have been optimal to use the same batch of particles for
both experiments in Figure 2.11, this was not possible because of the mass of particles
required for the release assay. However, this technicality does not prevent us from
concluding that when loading particles with resveratrol, a certain amount of the drug is
weakly associated with the surface and releases over a 24 hours period in our assay. For
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particles in the range of 4 to 5 µm, the surface associated resveratrol is a substantial
proportion (~60%) of the total resveratrol loaded. In contrast, surface associated resveratrol
makes up less than 20% of the resveratrol loaded into larger particles (9 to 11 µm), allowing
them to exhibit a more sustained release profile.
We suspected that the surface area to volume ratio played a role in the increase in
loading and burst release in the smaller particles. Looking at the surface area to volume
ratio (SA/V), the small particles had a SA/V of 1.5 and large particles had a SA/V of 0.6.
This is about a 3-fold increase in SA/V from small to large particles. The burst release after
24 hours increases by about 3-fold (20 to 60%) which matches this calculation. The ethanol
wash showed an increase of at least 4-fold between the smaller and large particles (2080%), which is higher than expected. This could be because the ethanol is washed for 1
minute and there may be some internal resveratrol washed out as well.
2.4. Discussion
Our goal was to develop PLG microparticles for the controlled release of
resveratrol. Our initial approach was to utilize a single emulsion/solvent evaporation
protocol that maximized resveratrol’s solubility in the oil phase by using ethanol as a cosolvent. We achieved PLG particles with a loading of 65 µg/mg and resveratrol remained
bioactive. Interestingly, the particles had ruffled surfaces atypical of particles produced by
emulsion, which have a smooth surface to minimize interfacial free energy100. We believe
the irregular morphology is due to interfacial instabilities that arise at the oil/water interface
as the solvents diffuse out of the oil droplet. We propose that during solvent removal, the
decrease in interfacial surface area of the shrinking droplet leads to an interfacial excess of
resveratrol, which decreases surface tension and causes droplet expansion. The expansion
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Figure 2.11. The effect of particle size on resveratrol release. (A) A comparison of
release profiles for 4 and 11 µm particles with drug loadings of 4.7 and 2.5 µg/mg,
respectively. (B) Resveratrol removed from particles after submersion in ethanol for 1
minute. Two batches of resveratrol particles were assayed: 9 µm, 2.1 µg/mg and 5 µm,
4.5 µg/mg. All measurements were carried out in triplicate. Data is mean ± standard
deviation. Resveratrol removed was analyzed with an unpaired t-test. **** indicates pvalue<0.0001.
manifests as folding and deforming of the interface that does not reverse prior to the
polymer’s phase transition when the particle hardens. In support of our explanation, surface
ruffling was described for a similar system in which polystyrene, chloroform, and nhexadecanol were emulsified in an aqueous solution of sodium dodecyl sulfate101. By
increasing the concentration of n-hexadecanol or the rate of solvent evaporation, both of
which promote interfacial excess of n-hexadecanol, the authors tuned the surface
topography of the polystyrene particles from smooth to ruffled.
While the irregular shaped particles had the highest drug loading (65 µg/mg), they
also exhibited variable drug release at early time points. We sought to improve drug release
by producing smooth, spherical particles. By decreasing resveratrol and increasing PVA in
the emulsion we achieved smooth particles, but the cost was a 15 to 25-fold decrease in
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drug loading depending on particle size. In addition, resveratrol was still present on the
surface of these particles, which caused 5 µm particles to release 60% of their payload in
24 hours compared to 20% for larger, 10 µm particles. The impact of particle size on
loading and release for small molecules encapsulated in PLG has been studied by several
groups102–105 and our findings are consistent. To summarize, drug loaded on the
microparticle’s surface contributes to burst release, and when there is substantial surface
loading of the drug, small particles have higher drug loading due to their greater specific
surface area relative to large particles. Interestingly, none of the small molecules in these
studies (dexamethasone, piroxicam, gefitinib) impacted particle morphology. We
hypothesize that resveratrol exhibits greater surface activity in our emulsion compared to
the other molecules in their emulsions.
An interesting finding was that resveratrol and PVA compete for the surface of the
particle during its formation. We observed this phenomenon indirectly in two ways: (i) a
decrease in resveratrol loading with increasing concentrations of PVA in the aqueous phase
and (ii) a decrease in fluorescence intensity of resveratrol particles emulsified with FITCPVA, indicating a decrease in PVA on the particle surface. PVA acts as an emulsifier in
our system and prevents coalescence of the oil droplets. The decrease in mass yield of the
1:3 particles when made with resveratrol (67±7 %, no resveratrol versus 40±5 %, 10
mg/mL resveratrol) indicates a consequence of PVA displacement is partial breakdown of
the emulsion before particles harden. Thus, another motivation to evenly distribute
resveratrol throughout the particle is to increase mass yield of the polymer particles (i.e.
the drug delivery system).
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To our knowledge, we are the first to functionalize PVA with FITC and use this
fluorescent emulsifier to study the surface of PLG microspheres. In the reaction, the
isothiocyanate group on FITC spontaneously reacts with an alcohol group on PVA and
forms a monothiourethane when stirred together at room temperature in DMSO106. This
straightforward and mild chemistry should be easily employed by any lab that produces
PLG particles using PVA as an emulsifier.
Currently, the resveratrol delivery rate and duration needed to induce weight loss
and affect other aspects of adipose tissue function have not been extensively investigated;
however, a study involving rats provides some guidelines89. Oral administration of
resveratrol at 30 mg/kg/day for six weeks decreased body fat in rats fed a high fat diet and
resveratrol metabolites were present in fat tissue at a concentration of 2.66 ± 0.55 nmol/g.
Unchanged resveratrol was not detected, likely due to its short half-life, which is 9.2 hours
in humans when administered orally29. Assuming humans would require 3 nmol/g of
resveratrol delivered to visceral adipose tissue per day and given that an adult male has 500
g of visceral fat107, a drug delivery system would need to release 345 µg/day. The time
averaged delivery rate for the 65 µg/mg particles was 1.2 µg/mg/day over six weeks. 345
µg/day would require less than 300 mg of particles distributed throughout 500 g of fat
tissue. There is precedence for delivering this amount of polymer to humans. For example,
a typical dose of VIVITROL microspheres, which are naltrexone encapsulated into 75:25
PLG, is 1 g injected intramuscularly108. Thus, we believe it is warranted to begin
investigating the therapeutic efficacy of the ruffled particles in pre-clinical models of
obesity; however, we will simultaneously work towards developing particles with higher
resveratrol loadings and optimal drug release rates.
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To develop particles for optimal resveratrol delivery, it will be necessary to
understand why resveratrol accumulates at the surface of PLG particles in the emulsion.
One possibility is that ethanol may have enhanced resveratrol’s surface activity by
promoting its accumulation at the oil/water interface. We speculate that due to ethanol’s
high miscibility with water compared to DCM, it may have diffused out of the particle
more quickly without a large impact on polymer viscosity because PLG is not soluble in
ethanol. Due to resveratrol’s poor solubility in both DCM and water, it accumulated at the
oil/water interface leading to surface loading.
We think that the ability of the drug to deposit on the surface of the microparticles
is governed by its surface activity in the emulsion used to make the particles, with higher
surface activity leading to more surface deposition. While we do not know the orientation
of resveratrol when it inserts at the oil-water interface, we speculate that it orients
perpendicular to the interface with the benzene-1,3-diol in the aqueous phase and the
phenol group in the oil phase because we expect the benzene-1,3-diol to be more
hydrophilic than the phenol group. Thus, we think the number of hydroxyl groups and their
orientation relative to each other on the stilbene impacts surface activity, with orientations
that increase the hydrophilicity at one end of the molecule relative to the other resulting in
a molecule with higher surface activity. Pinosylvin, with a benzene-1,3-diol and a benzene
ring on either end of the double bond is expected to exert more surface activity, while transstilbene, with no hydroxyl groups is expected to exhibit lower surface activity than
resveratrol. Trans-4-hydroxy stilbene may exhibit similar surface activity if the phenol
group exerts a sufficient level of hydrophilicity and it is difficult to predict piceatannol’s
activity since either end of the molecule boasts two hydroxyl groups. However, we
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recognize that the way these molecules will interact with other molecules at the interface
(i.e. water, ethanol, dichloromethane, poly(vinyl alcohol)) is difficult to predict, and future
studies that involve molecular modeling may be necessary to truly understand this. Future
studies will also investigate if a single-solvent oil phase can improve resveratrol loading
while preserving a smooth particle surface and controlling drug release.
2.5. Conclusion
We demonstrate that resveratrol, a molecule that is not soluble in DCM but soluble
in ethanol, can be encapsulated into PLG microspheres using an oil-in-water
emulsion/solvent evaporation technique with ethanol as a co-solvent. Increasing the
volume fraction of ethanol in the oil phase increases resveratrol’s solubility and subsequent
loading in the particle. Some of the resveratrol loads onto the particle surface, which may
be a property inherent of resveratrol, due to the presence of ethanol, or some combination
thereof. Nevertheless, there is a point where resveratrol’s density on the particle surface
leads to ruffling. Particles with this morphology exhibit variable drug release at early time
points. By decreasing resveratrol and increasing PVA in the emulsion, smooth particles are
produced, and drug release is controlled by particle size; however, drug loading is low.
Future work will design a particle with high drug loading and low variability in drug
release.
Broadly, this work serves as a cautionary tale that inclusion of a co-solvent in the
oil-in-water emulsion/solvent evaporation technique may impact drug distribution and,
possibly, particle morphology. On the other hand, we demonstrate that bioactive payloads
can be used to tune surface roughness of their drug delivery vehicle, which may afford
greater control over drug delivery by modulating biomaterial-tissue interactions.
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Figure 2.12. A comparison of particle size distribution using dynamic light
scattering (DLS) and image analysis. (A) Particle size distribution for a batch of
PLG particles measured with Malvern Zetasizer (a DLS instrument). DLS analysis
yielded an average particle diameter of 1.72 µm with a PDI of 0.225. (B) Size
distribution of the same particles using light microscopy and image analysis
described in section 2.2.4. Image analysis yielded an average particle diameter of
1.81±0.9 µm.

Figure 2.13. Particle size analysis of polystyrene beads measured with light
microscopy. (A) 10 µm, (B) 20 µm and (C) 50 µm polystyrene beads purchased from
Duke standards. The mean particle size and standard deviation measured using light
microscopy and image analysis methods in described section 2.2.4 is listed below the
image.
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Figure 2.14. Representative standard curve
for resveratrol dissolved in DMSO containing
PLG at 1 mg/mL.

Figure 2.15. Light microscopy of RSV particles depicted in Figure 2.2A before (A)
and after (B) lyophilization. Particles with no resveratrol (C) have spherical shapes,
suggesting lyophilization does not cause irregular particle formation.
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Figure 2.16. Resveratrol Standard Curve via
HPLC. Validation of UV-Vis analysis was done
via HPLC of resveratrol loading of irregular
particles shown in Figure 2.2A. Loading of
resveratrol was found to be 69±7 ug/mg, which
was very close to 65±5 ug/mg found via UV-Vis.

Figure 2.17. Flowability of particles. Particles in an Eppendorf tube before (A)
and after (B) spinning on the axis. Particles flow and take the shape of the
container.
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Figure 2.18. SEM image of particles fabricated
with 5% PVA in the emulsion. Conditions used
were 1:3 ethanol to DCM, 10ug/mg resveratrol,
7000 rpm for 30 seconds, and 5% PVA in the
emulsion step and 0% PVA in evaporation step.
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CHAPTER 3
FABRICATION OF BIODEGRADABLE PARTICLES WITH TUNABLE
MORPHOLOGIES BY THE ADDITION OF RESVERATROL TO OIL IN
WATER EMULSIONS.2
3.1 Introduction
The oil in water (O/W) emulsion/solvent extraction technique for making
biodegradable polymer particles involves dissolving a polymer in an organic solvent
(typically dichloromethane, DCM) and homogenizing in an aqueous solution of an
emulsifier (typically polyvinyl alcohol, PVA). The two phases are immiscible, and
spherical droplets are produced because this geometry minimizes interfacial energy. The
emulsion is then added to a large volume of aqueous solution and the organic solvent is
extracted from the dispersed phase, which results in the polymer precipitating and
hardening into particles. The particles are then recovered through centrifugation. This
technique is one of the most studied and utilized for producing polymer particles because
of its versatility and scalability, and it is used for several FDA approved polymer-based,
controlled-release therapies such as Vivitrol57, Lupron Depot109, and Risperdal110. The
O/W emulsion/solvent extraction technique allows for tuning of many particle properties
including, size, drug release rate, and surface chemistry54,58. However, altering particle
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morphology is challenging because of the tendency of this emulsion system to form
spheres62. Tuning particle morphology is of interest because it impacts cell-material
interactions and subsequent biological responses49. Cells interact differently with
nonspherical particles than spherical ones61,64,111. For example, macrophages internalize
ellipsoidal particles in an orientation dependent manner. The long end of the ellipsoid is
internalized more readily than the flat side61. Additionally, fibroblasts attach more readily
to particles with a wrinkled surface than those that are smooth64. Finally, nonspherical
particles cause maturation of dendritic cells to a greater extent than spherical particles111.
Particle fabrication techniques used in these studies include particle film stretching61,
photopolymerization64, and microfluidics111. While these methods are elegant, they are
technically challenging and do not have a history of implementation in GMP
manufacturing54,112. Thus, while these studies demonstrate the importance of particle
morphology on the biological response, the particle fabrication techniques employed may
be difficult to adapt to the pharmaceutical industry44,113.
The scalability of the O/W emulsion technique makes it attractive for making
nonspherical particles at an industrial scale. As a point of comparison, photopolymerization
and lithography produce approximately 106 particles per day with constant operation; in
contrast, a bench-scale O/W emulsion batch process produces 109 particles in a matter of
hours and is only limited by the size of the vessel62. While nonspherical particles have been
achieved using O/W emulsion systems114, they required poloxamer surfactants that have
yet to be incorporated in an FDA approved polymer particle controlled release therapy44.
Taken together, a methodology to modulate particle morphology that utilizes the
DCM/PVA emulsion system would be highly desirable.
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Recently, we investigated poly(lactide-co-glycolide) particles for delivery of
resveratrol to fat tissue, a small molecule with anti-obesity properties26 and an established
safety profile in humans28. To accomplish this, we developed a method to encapsulate
resveratrol within the particles using the DCM/PVA emulsion system by utilizing ethanol
as a cosolvent in the oil phase68. Unexpectedly, we found that the incorporation of
resveratrol into the particles led to a non-spherical morphology. While the previous study
evaluated the particles for controlled released of resveratrol, an investigation into why the
emulsion system produced non-spherical particles was not carried out. Herein, we sought
to study the system by investigating the effect of cosolvent, primary solvent and type of
stilbene on particle morphology. In addition, we investigate its applicability to additional
polyesters used in FDA approved devices115 and demonstrate an ability to encapsulate a
model hydrophobic drug, coumarin 6. Taken together, the data presents a facile method for
controlling the morphology of polyester particles. Given the importance of particle
morphology in cell-material interactions, our findings may aid in the field’s ability to
control biological responses with biocompatible particulate systems.
3.2 Materials and Methods
3.2.1 Materials
75:25 poly(D,L-lactide-co-glycolide) (PLG) with a lauryl ester end group and an
inherent viscosity of 0.79 dL/g and ester terminated polycaprolactone (PCL) with an
inherent viscosity of 1.24 g/dL were purchased from Evonik (Birmingham, AL).
Dichloromethane (DCM), resveratrol (RSV), poly(vinyl alcohol) (PVA) (MW 13,000–
23,000, 87–89% hydrolyzed), poly(L-lactide) (PLLA) with an ester end group and an
inherent viscosity of 1.1 dL/g, pinosylvin and coumarin 6 were purchased from Sigma (St.
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Louis, MO). Ethyl acetate (EA) was purchased from Macron Fine Chemicals (Center
Valley, PA) and trans-stilbene was purchased from TCI Chemicals (Portland, OR).
Piceattanol was purchased from Cayman (Ann Arbor, MI). Methanol (MeOH) and acetone
were purchased from BDH Chemicals (Radnor, PA). Ethanol (ETOH) was purchased from
Decon Laboratories (King of Prussia, PA). Dimethyl sulfoxide (DMSO) was purchased
from Fisher (Hampton, NH). Ultrapure water was obtained from a Thermo Scientific
Barnstead Nanopure system.
3.2.2 Polymer Particle Fabrication
Polymer particles were prepared using a single oil-in-water emulsification/solvent
extraction method as described previously with modifications

95

. Briefly, polymer was

dissolved in organic solvent at a concentration that would achieve a final organic phase
concentration of 6% (wt/wt), hereafter simply “6%”. If a stilbene was included, it was
dissolved in cosolvent and added to the organic phase for final concentrations and
cosolvent proportions listed in Table 3.1. For the emulsion, 0.6 mL of organic phase was
added dropwise into 4 mL of an aqueous solution of 1% (wt/v) polyvinyl alcohol (PVA),
hereafter simply “1%”, and homogenized at 7000rpm for 30s using a Kinematica PT3100D
homogenizer. Solvent extraction was then conducted by adding the homogenization
mixture to 16 mL of ultrapure water and then stirring the mixture for 5 hours. This allows
the organic solvent to extract and evaporate and the resulting particles to harden. The
particles were then passed through a 40 µm filter (Greiner Bio-one), collected via
centrifugation at 1750xg and washed 4 times in ultrapure water. Washed particles were
frozen at -20°C and subsequently lyophilized overnight with a Labconco freeze dryer.
Recovered particles were stored under vacuum in a dry environment at room temperature.
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For coumarin 6 loaded particles, all conditions were the same as the first formulation in
Table 3.1, except coumarin 6 was added to the organic phase at 0.5 mg/mL.
Table 3.1. Conditions used for particle formulations.
Primary
Cosolvent

Stilbene

Volume %

concentration

of cosolvent

Stilbene

Solvent

Polymer

DCM

ETOH

Resveratrol

10 mg/mL

25%

PLG

DCM

MEOH

Resveratrol

10 mg/mL

25%

PLG

DCM

Acetone

Resveratrol

10 mg/mL

25%

PLG

DCM

ETOH

Resveratrol

4 mg/mL

25%

PLG

DCM

ETOH

Resveratrol

0 mg/mL

25%

PLG

DCM

ETOH

Resveratrol

4 mg/mL

10%

PLG

DCM

ETOH

Resveratrol

10 mg/mL

25%

PCL

DCM

ETOH

Resveratrol

10 mg/mL

25%

PLLA

DCM

ETOH

Piceattanol

10 mg/mL

25%

PLG

DCM

ETOH

Pinosylvin

10 mg/mL

25%

PLG

DCM

ETOH

25%

PLG

0%

PLG

Trans10 mg/mL
Stilbene
EA

None

Resveratrol

10 mg/mL

DCM: dichloromethane; EA: ethyl acetate; ETOH: ethanol; MEOH: methanol; PLG:
poly(lactide-co-glycolide); PCL: polycaprolactone; PLLA: poly(L-lactide).
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3.2.3 Video microscopy of particle formation
Particle formation was visualized under a Nikon Eclipse Ci microscope after the
emulsion process had taken place. After homogenization, 10 µL of the emulsion was
transferred onto a glass slide. This was then observed under the microscope while images
were acquired every second for 5 minutes, which was a sufficiently long time that no more
particle formation was observed. Videos were made with a frame rate of 10 images per
second.
3.2.4 Powder X-Ray Diffraction
A Rigaku MiniFlex X-ray diffractometer with high sensitivity 1D silicon strip
detector (D\teX Ultra) was used to detect the presence of crystalline structure within the
particles. 10 mg of samples were spread on zero-background holders for analysis. PXRD
was performed over a range of 5-80° 2𝜃 at room temperature at a scan rate of 2°/min. An
x-ray source with Cu target at 30kV and 15mA was used to generate Cu Kα x-rays
(λ=1.54059Å) for analysis. Diffraction was recorded as intensity vs. 2𝜃. Peak fitting was
performed using Fityk curve fitting program116.
3.2.5 Sessile Drop
To qualitatively determine interfacial tension of the emulsion system, a sessile drop
experiment of the aqueous and organic phases was employed. 4 mL of aqueous phase (1%
PVA) was added to a 20 mL scintillation vial. Into this, 0.3 mL of organic phase was
carefully added to the bottom of the vial. Images were then taken from a level surface and
relative height and angle of contact analyzed.

47

3.2.6 Scanning Electron Microscopy (SEM) and Light Microscopy (LM)
Carbon adhesive tape was attached to aluminum SEM stubs, and particles were
spread onto the stubs. Compressed air was applied briefly to the particles to create a
monolayer on the carbon tape. Particles were sputtered with gold 3 times for 60 seconds in
a Denton Desk II Vacuum sputter coater. Images were taken using a TESCAN Vega3
Scanning Electron Microscope at 10kV.
Light and fluorescence microscopy images of particles were taken on an EVOS FL
microscope at 20x magnification. Particles were prepared in ultrapure water and suspended
at a concentration of 0.25 mg/mL. 400 µL of these suspensions was added to a well of a
48-well plate and allowed to settle prior to image acquisition. Fluorescence images were
taken on the green GFP (470nm) fluorescence setting.
3.2.7 Measurement of Particle Size
Particle size was found by analyzing light microscopy images using ImageJ
software. Briefly, three representative images were taken of each particle condition and
converted to binary (B/W) colors. The Particle Analysis plugin in ImageJ was used to
measure particle diameter. We report the mean particle diameter and the coefficient of
variation (CV%), which is the standard deviation divided by the mean. We validated this
method previously 68 by accurately measuring the size of purchased polystyrene beads.
3.2.8 Mass Yield and Resveratrol Loading
Mass yield was calculated by dividing the mass of recovered particles by the mass
of polymer and resveratrol emulsified. Particle mass yield was calculated according to
equation 1.
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𝑀𝑎𝑠𝑠 𝑌𝑖𝑒𝑙𝑑 (%) = (𝑀

𝑀𝑃𝑇

𝑃𝑜𝑙 +𝑀𝑅𝐸

) ∗ 100

(1)

Where MPT is the mass of particles recovered from the emulsion, MPol is the mass of
polymer added to the emulsion, and MRE is the mass of resveratrol added to the emulsion.
Resveratrol content was determined by dissolving 1 mg of particles in 1 mL DMSO
and measuring absorbance at 330 nm using a Spectramax 190 UV-Vis spectrophotometer.
A 10-point standard curve was prepared by dissolving 1 mg of empty particles and a known
mass of resveratrol in DMSO. Resveratrol concentration was determined by comparing the
unknown samples to the standard curve. Resveratrol loading (µg/mg) was calculated by
dividing the mass of resveratrol extrapolated from the standard curve by the mass of
particles dissolved in DMSO. Resveratrol loading was calculated by equation 2.
𝜇𝑔

𝑀

𝐿𝑜𝑎𝑑𝑖𝑛𝑔 (𝑚𝑔) = 𝑀𝑅

(2)

𝑃

Where MP is the mass of particles dissolved in DMSO and MR is the mass of resveratrol
measured in those particles.
3.2.9 Calculation of surface area
Surface area of particles was determined by the Brunauer Emmet Teller (BET) gas
adsorption method117 using krypton adsorption isotherms measured using a Micromeritics
ASAP 2020 physisorption instrument. Approximately 250 mg of particles were weighed
out in a glass sample tube and degassed for 12 hours at 30°C. Krypton adsorption
measurements were then carried out at 77K up to P/P0 = 0.3. BET transformation of the Kr
adsorption isotherms was fit with linear regression over appropriate range. Linear fitting
of BET transform plot was considered acceptable above an R2 of 0.999. We validated that
our protocol would provide accurate, reproducible measurements by analyzing 250 mg of
a low surface area silica standard (0.20±0.03 m2/g) provided by Micromeritics in three
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independent experiments (Table 3.2.) The average value for the three trials fell within the
reported range of the low SA alumina standard. Surface area measurements of polymer
particles were then run 1 or 2 times for each condition.
Table 3.2. Surface area measurements of low surface area silica standard
Trial # (Date)

BET Surface area (m2/g)

1 (11/16/19)

0.1703±0.0045

2 (11/21/19)

0.1730±0.0014

3 (11/22/19)

0.1757±0.0014

3.2.10 Differential centrifugation of nonspherical particles
Particles were separated by size based on the principle that large particles sediment
more readily than small particles. For our system, we found that 10 minutes of
centrifugation at 1xg sedimented 25 µm particles while 30xg sedimented 6 µm particles
and 250xg sedimented 2 µm particles and smaller. We suspended 50 mg of nonspherical
particles in 40mL water in a 50mL centrifugation tube and centrifuged at 1xg for 10
minutes. The supernatant was then collected and centrifuged for 10 minutes at 30xg.
Finally, the supernatant of the second spin was centrifuged at 250xg for 10 minutes. This
produced particles in size ranges of 2 µm – 6 µm, 6 µm – 25 µm, and 25 µm and larger.
Particle sizing is described earlier in the methods.
3.3 Results
3.3.1 Observing particle formation with video microscopy.
Previously, we reported that the addition of resveratrol to the oil phase of a
DCM/PLG/PVA/H2O emulsion using ethanol as co-solvent led to the formation of
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nonspherical particles with creased or wrinkled surfaces68. To visualize the process by
which the oil droplets become nonspherical particles, we imaged particle formation using
video microscopy. This was achieved by forming the emulsion and then rapidly
transferring a small sample to a glass slide for observation and video recording. We found
that in emulsions with resveratrol, droplets buckled and crumpled as they decreased in
volume, presumably as DCM and ethanol diffuse out of the droplet. In contrast, droplets
formed without resveratrol maintained spherical geometry as their volume decreased (Fig
3.1). SEM images confirm that particles made with DCM or DCM and ethanol are
spherical, while most particles made with resveratrol are highly crumpled (Figure 3.1,
fourth column). The video microscopy indicates that when resveratrol is incorporated into
the emulsion, the droplet deviates from its spherical form as volume is decreased leading
to a crumpled morphology.
3.3.2 XRD analysis
We next sought to determine if the resveratrol was crystalline in the particles made
with the small molecule. To determine this, we conducted X-ray diffraction (Figure 3.2,
PLG+RSV, blue line). For comparison, we also investigated free resveratrol (RSV, black
line), particles made without resveratrol (PLG, orange line), and a physical mixture of the
two (PLG+RSV Mixed, yellow line). Particles made with resveratrol had a loading of 65
µg/mg or 6.5%, and thus, the physical mixture was 6.5% resveratrol by mass.
The diffractogram for free resveratrol indicated it was crystalline with several sharp
diffraction peaks at 7.0, 16.7, 19.6 and 28.6° among others. The amorphous nature of the
particles made without resveratrol was evidenced by a broad peak between 10 and 25°. The
physical mixture of resveratrol and particles exhibited several diffraction peaks (including
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Figure 3.1. Images from video microscopy of particle formation with
corresponding SEM images. The results of three emulsions are shown. For all cases,
the concentration of PLG in the oil phase is 6% and the concentration of PVA in the
aqueous phase is 1%. The formulation of the oil phase varies by row. The top row is
100% DCM. The middle row is 75% DCM and 25% ethanol (ETOH). The bottom row
is 75% DCM, 25% ETOH and 10 mg/mL resveratrol (RSV). Frames are shown from
the beginning of video acquisition (t=0), midway through the video (t=1/2) and at the
end of the video when particle size has stabilized (t=final). Red arrows indicate the
same droplet over time for each condition. SEM images of the particles are shown in
the right-hand column.
7.1, 16.9, 19.9, 29.0°), indicating crystalline resveratrol could be detected at the weight
percent used (6.5%). The diffractogram for the particles made with resveratrol exhibited
peaks at 7.0, 16.8, 19.6 and 28.7°, similar to those observed in the physical mixture (albeit
they were smaller). The data suggest that a small amount of the resveratrol may be
crystalline in the particles made with the small molecule.
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Figure 3.2. X-ray diffraction of resveratrol and PLG particles. Diffractogram of
free resveratrol (RSV, black curve), PLG particles (PLG, orange curve), particles made
with resveratrol with a loading of 65 µg/mg (PLG+RSV, blue curve) and a physical
mixture of particles and resveratrol that was 6.5% resveratrol by mass (PLG+RSV
Mixed, yellow curve). Curves are displayed as Intensity vs. 2𝜃. Diffraction peaks
shared by the particles containing resveratrol (blue curve), the physical mixture of
particles and resveratrol (yellow curve,) and free resveratrol (black curve) are indicated
with dotted blue lines with the corresponding 2𝜃 measurement reported directly above
the line.
3.3.3 Sessile drop analysis of interfacial tension
Decreasing interfacial tension of an emulsion can lead to deviations from spherical
morphology101,111. To determine if resveratrol was affecting interfacial tension, we
employed the sessile drop method to study the shape of a drop of the organic phase in the
aqueous phase. In this method, the height of the drop is directly proportional to the
interfacial tension between the two phases118. Figure 3.3A shows that PLG dissolved in
DCM pipetted into an aqueous solution of PVA forms a sessile drop on the bottom of the
vial. Fig 3.3B indicates that when the organic phase (PLG+DCM) contains 25% ethanol
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the drop decreases in height, indicating the interfacial tension is decreased, which is
consistent with another study97. In Figure 3.3C, resveratrol is added to the organic phase
containing DCM, PLG and ethanol. The resveratrol can be seen diffusing into the aqueous
phase as a white precipitate. The drop containing resveratrol appears to have a similar
height to the drop containing only DCM and PLG (Fig. 3.3A), suggesting the addition of
resveratrol nullifies the decrease in interfacial tension caused by the ethanol.

Figure 3.3. Effect of ethanol and resveratrol on sessile drop formation. Image
of sessile drops formed by pipetting the organic phase into aqueous solution of PVA.
Aqueous phase is 1% PVA in water. The organic phase is 6% PLG dissolved in A)
100% DCM, B) 25% ethanol 75% DCM and C) 25% ethanol 75% DCM and 10
mg/mL resveratrol. Arrows delineate the organic droplet against the bottom of the
vial.
3.4 Effect of hydroxyl group number and placement on particle morphology
Resveratrol is a trans-stilbene derivative where hydroxyl groups reside at the 3, 5,
and 4’ positions relative to the double bond (Figure 3.4C). We hypothesized that hydroxyl
group number and placement would impact particle morphology. Thus, we produced
particles with trans-stilbene, which has no OH groups, pinosylvin, which lacks the 4’ OH
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group of resveratrol, and piceatannol, which has an additional OH group at the 3’ position
when compared to resveratrol (Figure 3.4). We found that incorporation of trans-stilbene
or pinosylvin into the emulsion resulted in spherical particles. In contrast, incorporation of
piceatannol largely inhibited particle formation. The mass yield of particles dropped from
60% (for trans-stilbene) to 12% for piceatannol, making it difficult to study the piceatannol
particles via microscopy (Figure 3.4D). The particles that did form in the presence of
piceatannol appeared irregular in shape. We conclude that the degree of hydroxyl
substitution impacts emulsion stability. Furthermore, of the trans-stilbene derivatives
investigated, the number and placement of hydroxyl groups in resveratrol appear to be
optimal for inducing crumpled particle morphology at the conditions tested.
3.3.5 Relative contributions of ethanol and resveratrol on particle morphology
We next investigated the relative contributions of ethanol and resveratrol on particle
morphology. Decreasing the resveratrol concentration from 10 mg/mL (used to make the
particles depicted in Figure 3.1 and 3.4C) to 4 mg/mL, while maintaining the ethanol
concentration at 25%, led to particles that were mostly spherical; however, we did observe
a small population of particles with crumpled morphology (Figure 3.5 A,D, red arrows).
Particles made this way had relatively low resveratrol loading, 1.5 µg/mL. Particles made
with 25% ethanol, but no resveratrol were spherical, indicating resveratrol is required for
particle crumpling (Figure 3.5 B,E). Interestingly, when ethanol concentration was
decreased to 10% while maintaining resveratrol at 4 mg/mL, particles were also spherical
(Figure 3.5 C,F) and had a resveratrol loading of 4 mg/mL, which was 2.6-fold higher
compared to the conditions in Figure 3.5 A,D. The data suggests that resveratrol loading
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Figure 3.4. Effect of resveratrol-like molecules on particle morphology. Particles
were made with an organic phase that was 25% ethanol, 75% DCM, and 6% PLG. In
addition, the organic phase contained a stilbene at 10 mg/mL. The stilbenes
investigated were (A) trans-stilbene, (B) pinosylvin, (C) resveratrol, or (D)
piceatannol. Light microscopy images are shown along with the stilbene’s structure
and logP. The mass yield of particles is also listed. Scale bars indicate 50 µm.
may not be the defining factor that dictates particle morphology and that ethanol may
enhance resveratrol’s effect on particle buckling and crumpling.
3.3.6 The effect of cosolvent on particle morphology
Here, we sought to understand the effect of cosolvent on particle morphology. To
accomplish this, we fabricated particles using either ethanol, methanol, or acetone as the
cosolvent. All three solvents are able to solubilize resveratrol to a similar degree (50
mg/mL, Table 3.3). One difference between these three solvents is their solubility in water,
which is also reflected by their LogP values (Table 3.3). Specifically, methanol is about
twice as soluble in water as acetone, and ethanol’s solubility resides in between methanol
and acetone. An additional difference is that PLG is soluble in acetone at 6%, but not in
ethanol or methanol (Table 3.3).
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25%, 0mg/mL

25%, 4mg/mL

10%, 4mg/mL
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Figure 3.5. Relative contributions of ethanol and resveratrol on particle
morphology. (A-C) Light microscopy images and (D-F) SEM images of particles
made with differing amounts of resveratrol and ethanol in the oil phase. (A,D) 25%
ethanol and 4 mg/mL resveratrol, (B,E) 25% ethanol and 0 mg/mL resveratrol, (C,F)
10% ethanol and 4 mg/mL resveratrol. Red arrows indicate crumpled particles. Scale
bars indicate 50 µm.
Utilizing ethanol as the cosolvent resulted in many highly crumpled particles and
some smaller particles that were spherical (Figure 3.6A,D). Resveratrol content of the
particles made with ethanol was 65 µg/mg. Utilizing methanol as the cosolvent also
resulted in crumpled particles and a population of spherical particles that tended to be
smaller than the nonspherical particles (Figure 3.6B,E). Resveratrol content of particles
made with methanol was 50 µg/mg. Finally, when acetone was used as the cosolvent,
particle morphology resembled collapsed spheres, with deep indentations (Figure 3.6C,F).
Once again, spherical particles were also observed, but they tended to be smaller than the
nonspherical particles. Resveratrol content of particles made with acetone was 18 µg/mg.
In addition, particles made with methanol or acetone, but without resveratrol, were
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Table 3.3. Solvent Properties 119–121
RSV Solubility

6% PLG

Solubility in

(mg/mL)

solubility

Water

LogP

Methanol

50

No

31.21 M

-0.77

Ethanol

50

No

21.71 M

-0.31

Acetone

50

Soluble

17.22 M

-0.24

Ethyl Acetate

10

Soluble

0.91 M

0.73

Dichloromethane

None

Soluble

0.15 M

1.25

Solvent

spherical (data not shown), which was the case when ethanol, but no resveratrol was used
(Figure 3.1).
To quantify the differences in morphology between the particles formed with the
three cosolvents, we calculated surface area using krypton gas adsorption measurements
and BET theory. Particles made with ethanol, methanol, and acetone had specific surface
areas of 1.2, 0.91, and 0.71 m2/g, respectively. The data indicates the crumpled morphology
achieved with ethanol has 70% higher specific surface area than the collapsed spheres made
with acetone. In addition, we find surface area correlates with resveratrol content.
3.3.7 Effect of ethyl acetate as the organic solvent on particle morphology
The data up to this point led us to hypothesize that the two solvent system involving
DCM and a cosolvent was causing nonspherical particle formation. Thus, we searched for
a solvent able to solubilize both PLG and resveratrol. We found that resveratrol was soluble
up to 10 mg/mL in ethyl acetate containing 6% PLG (Table 3.3). In addition, ethyl acetate
has been used to make PLG particles using PVA as the emulsifier122. Particles fabricated
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DCM+Ethanol

DCM+Methanol

DCM+Acetone

A

B

C

D

E

F

65 µg/mg
1.2 m2/g

50 µg/mg
0.91 m2/g

18 µg/mg
0.71 m2/g

Figure 3.6. The effect of cosolvent on particle morphology. Representative images
of PLG particles made with organic phases that were: (A,D) 25% ethanol and 75%
DCM, (B,E) 25% methanol and 75% DCM, and (C,F) 25% acetone and 75% DCM.
(A-C) are light microscopy images and (D-F) are SEM. The oil phase contained 6%
PLG and 10 mg/mL RSV. The aqueous phase contained 1% PVA. Scale bars indicate
50 µm. Resveratrol loading is listed for each formulation in ug/mg. Surface area was
determined by BET theory applied to Krypton adsorption isotherms and is listed in
m2/g.
using ethyl acetate containing the same concentrations of resveratrol (10 mg/mL) and PLG
(6%) as the DCM/ethanol system were smooth and spherical instead of crumpled (Figure
3.7). Particles made with ethyl acetate had similar loading to the highest loaded particles
made with DCM and ethanol (57 µg/mg vs 65 µg/mg), but a lower surface area (0.78 m2/g
vs 1.2 m2/g). This was expected because the particles made with ethyl acetate were
spherical. Thus, we conclude that particle buckling that leads to the crumpled morphology
is specific to when particles are made with resveratrol, and DCM is used with a cosolvent.
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B

A

Figure 3.7. Effect of Ethyl Acetate on particle morphology. Light microscope (A)
and SEM (B) images of resveratrol loaded particles made with ethyl acetate as the
organic solvent. The oil phase contained 10 mg/mL resveratrol and 6% PLG. The
aqueous phase contained 1% PVA. Resveratrol loading was 57 µg/mg and the surface
area was calculated to be 0.78 m2/g. Scale bars indicate 50 µm.
3.3.8 Production of nonspherical particles using polycaprolactone and poly(L-lactide)
We were interested if crumpled particles could be produced from other polyesters
that have been FDA approved for use in medical devices and drug delivery systems. We
found that nonspherical particle formation could be achieved using polycaprolactone
(PCL) or poly(L-lactide) (PLLA), which is demonstrated in Figure 3.8 A and C. To confirm
that resveratrol was required for nonspherical particle formation, we made particles without
resveratrol (blank particles) and confirmed they were spherical (Figure 3.8 B,D).
Interestingly, the PCL particles were larger than the PLLA particles, which were similar in
size when compared to PLG particles made without resveratrol. The PCL particles were
probably larger because the PCL used has a higher inherent viscosity than the other two
polymers and will naturally form larger droplets in the emulsion58.
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PCL+RSV

PCL Blank

B

A

PLLA+RSV

C

PLLA Blank

D

Figure 3.8. Morphology of polycaprolactone (PCL) and poly(L-lactide) (PLLA)
particles made with resveratrol. Representative images of particles made with an
oil phase consisting of (A,C) 25% ethanol and 75% DCM and 10 mg/mL of
resveratrol or (B,D) 100% DCM with no resveratrol. (A,B) were made with an oil
phase that was 6% PCL and (C,D) were made with an oil phase that was 6% PLLA.
The aqueous phase of the emulsion contained 1% PVA. Scale bars indicate 50 µm.
3.3.9 Incorporation of coumarin 6 into resveratrol loaded particles
One application of nonspherical particles is drug delivery, and we investigated if a
hydrophobic agent could be encapsulated in the crumpled particles formed with resveratrol.
As proof of concept, we added coumarin 6, a hydrophobic fluorochrome, to the oil phase
containing ethanol, DCM, PLG and resveratrol. These particles formed with the same
crumpled morphology as particles produced without coumarin 6 (compare Figure 3.9A
with 6A) and were highly fluorescent (Figure 3.9B), indicating coumarin 6 was
successfully encapsulated. Encapsulating coumarin 6 in the absence of resveratrol resulted
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in smooth particles, demonstrating that coumarin 6 does not have an effect on particle
morphology (Figure 3.9 C,D). These results suggest that hydrophobic bioactive agents
could be encapsulated into the crumpled particles for drug delivery applications.
3.10 Separation of nonspherical particles by size
Particle size impacts drug release kinetics103. Size also dictates how a biological
system will interact with the particle. For example, particles smaller than 6 microns are
readily phagocytosed by macrophages, while larger particles are left to reside in the
extracellular space69. To demonstrate that nonspherical particles could be sorted based on
size, differential centrifugation was employed to separate particles made with 25% ethanol
and 75% DCM and 10 mg/mL of resveratrol. The process successfully separated 3 size
ranges, as can be seen in Fig. 3.10. Centrifugation at 1xg collected particles above 25 µm
(Figure 3.10A). A subsequent round of centrifugation at 30xg collected particles between
6 µm and 25 µm (Figure 3.10B). A final round of centrifugation at 250xg collected particles
that were less than 6 µm (Figure 3.10C). The images suggest that the frequency of crumpled
particles may decrease as size decreases.
3.4 Discussion
The O/W emulsion/solvent extraction technique is a simple and scalable method
for producing polymer particles and has been used in the fabrication of several FDA
approved polymer particle therapies54. However, it is challenging to produce particles of
nonspherical morphology, as O/W emulsions preferentially produce spherical particles.
Here we present a facile method for producing nonspherical PLG particles by adding
resveratrol and a cosolvent to the oil phase of a DCM/PLG/PVA/H2O emulsion. While
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Bright Field

Fluorescence

A

B

C

D

Figure 3.9. Coumarin 6 can be encapsulated into crumpled particles formed with
resveratrol. Particles were fabricated with an oil phase consisting of 25% ethanol,
75% DCM, 6% PLG, and 0.5 mg/mL coumarin 6 with (A, B) or without (C,D) 10
mg/mL resveratrol. Scale bar indicates 50 µm.
addition of resveratrol and ethanol produce particles with a “crumpled paper” morphology,
addition of resveratrol and acetone produce particles with a morphology that resembles
deflated or indented spheres. We demonstrate broad applicability of the technique by
producing nonspherical particles out of polycaprolactone and poly(L-lactide) in addition
to PLG. Importantly, PCL and PLL are slower degrading polymers compared to PLG.
Using polymers with varying degradation times can be used to modulate release rates for
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A

B

>25 µm

C

25 µm – 6 µm

<6 µm

Figure 3.10. Nonspherical particles can be separated by size using differential
centrifugation. Particles were fabricated with an oil phase consisting of 25%
ethanol, 75% DCM 6% PLG, and 10 mg/mL resveratrol. The aqueous phase was 1%
PVA. Particles were separated by size using differential centrifugation. Particles were
first centrifuged at 1xg (A), then at 30xg (B), and finally at 250xg (C) each for 10
minutes. These steps produced particles that were 25 µm and greater (A), 25 µm – 6
µm (B), and less than 6 µm (C).
drug delivery applications123. In addition, we co-encapsulate resveratrol with a
hydrophobic fluorescent dye, coumarin 6, which produces fluorescent nonspherical
particles. This result suggests hydrophobic bioactive agents could be encapsulated into the
crumpled particles for drug delivery applications. A previous study co-encapsulated
nonspherical particles with fluorescent molecules with a lithography approach124, but the
benefit of our system is that the O/W emulsion/solvent extraction is more scalable. Finally,
we show that using differential centrifugation we can purify large particles (>25 μm
particles) that could act as drug depots or smaller particles (less than 6 μm) that could be
endocytosed for intracellular drug delivery applications125,126.
To our knowledge, no other studies have reported production of crumpled or highly
deformed spherical particles using the O/W emulsion/solvent extraction technique70. Many
nonspherical particles have been produced using microfluidics, photopolymerization and
lithography. A wide variety of shapes have been made using these methods such as rods,
discs, rings, and wrinkled particles62,64,70. These methods have been successful in
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controlling morphology; however, those fabrication processes are not currently used to
make FDA approved controlled release formulations54 and they are less efficient than the
O/W emulsion/solvent extraction in terms of making large quantities of particles for
industrial purposes.
Video microscopy revealed that addition of resveratrol and ethanol to the dispersed
phase of the emulsion caused the spherical droplets to buckle as they decreased in volume
leading to a crumpled morphology. Generally, droplets in these emulsions (i.e.
DCM/PLG/PVA/H2O) remain spherical up until the polymers precipitate and the particle
forms. This is likely because there is sufficient mobility for the polymer chains to
reorganize and condense as droplet volume deceases (due to diffusion of DCM out of the
droplet). The buckling behavior observed when resveratrol and ethanol are added to the
emulsion is reminiscent of when a thin, spherical elastic shell is deformed by applying
external pressure or reducing the volume127. This phenomenon can be visualized with a
ping pong ball. When pressed on at a single location, with sufficient force, the shell indents.
If the ball is pressed on at multiple points with sufficient force, the shell crumples with
multiple indentations. It is unclear why the emulsion droplets crumple with the addition of
resveratrol and ethanol. The literature is rich with reports of encapsulating small molecules
in PLG particles102–105 and, to our knowledge, crumpled morphology was not observed,
even when ethanol was added to a DCM/PLG/PVA/H2O emulsion used to encapsulate
dexamethasone97. It does appear that the hydroxyl groups are optimally positioned on
resveratrol to induce the crumpled morphology because switching out resveratrol for
pinosylvin, which lacks the 4′ hydroxyl group, led to spherical particles, while using
piceatannol with the additional 3′ hydroxyl decreased particle yield to 12%, indicating
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particle formation was disrupted in some way. We think that resveratrol somehow restricts
chain motion of the polymers at the oil–water interface. The reduction in their fluidity
would introduce a shear modulus that could lead to buckling behavior as the droplet
decreases in volume128. XRD of the highly crumpled particles suggest that there may be
small amounts of crystalline resveratrol. Perhaps these crystalline regions form at the oil–
water interface during solvent extraction and restrict polymer chain motion as the droplet
shrinks. In support of this idea, a white precipitate is seen forming at the oil water interface
in the sessile drop experiment. Another possibility is that resveratrol molecules, rather than
crystals, restrict chain motion during droplet shrinkage. We propose that resveratrol might
accomplish this by hydrogen bonding with carbonyl groups in the PVA.
Cosolvent appears to play an important role in resveratrol-induced particle
crumpling. We believe this role is to transport resveratrol to the oil–water interface.
Addition of resveratrol to the DCM/PLG/PVA/H2O emulsion with the aid of ethanol,
methanol, or acetone all led to particle crumpling (albeit varying degrees, discussed below).
In contrast, when ethyl acetate was used instead of DCM, a cosolvent was not needed and
particles remained spherical. Furthermore, there is a dose dependence of cosolvent on
particle crumpling. When the oil phase contained 10% ethanol and 4 mg/mL resveratrol,
only spherical particles were observed; however, when ethanol was increased to 25%,
particle crumpling was detected in a small population of particles. We propose that as the
cosolvent leaves the droplet, some portion of the resveratrol is redistributed from the bulk
of the droplet to the surface, and greater redistribution is achieved by increasing cosolvent
concentration. Interestingly, particles made with 25% ethanol, which exhibited a low
frequency of particle crumpling, contained less resveratrol (2.5x less) than the those made
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with 10% ethanol. It is tempting to conclude that resveratrol content and particle crumpling
can be decoupled as long as sufficient resveratrol is transported to the oil-water interface.
However, we caution that the resveratrol measurements are an average value for the entire
batch of particles and may not reflect the true loading of the small population of crumpled
particles, which could have much higher resveratrol content than the smooth particles.
The cosolvent used had a dramatic effect on particle morphology in some cases. By
switching out ethanol for acetone we produced particles resembling deflated spheres with
few, large indentations rather than spheres that were highly crumpled. The shape of a
deformed thin spherical shell, which can vary from a sphere with a single indentation to
sphere with many indentations, which appears highly crumpled, depends on deformation
rate, extent of volume change, and the Foppl-von Karman (FvK) number127. The FvK
number is the ratio of shell radius to shell thickness scaled by Poisson’s ratio. Essentially,
shells with a larger FvK deform more readily and, thus, require a smaller volume change
in order to deform. Modeling indicates that for a given FvK and volume change, a large
deformation rate leads to the simultaneous formation of many indentations that culminate
in a high degree of crumpling, while a sufficiently slow deformation rate results in a single
indentation127. In fact, the modeling suggests there is a lower limit on deformation rate that
must be achieved otherwise only 1 or 2 indentations result127, and the morphology
resembles that of the particles made with acetone. We propose that deformation rate (i.e.
change in droplet volume) may be different for droplets formed with ethanol versus acetone
because ethanol has a higher solubility in water (Table 3.3) and could possibly leave the
droplet faster. Following this logic, using ethanol as a co-solvent leads to droplet
deformation rates that support multiple indentations and a highly crumpled surface when
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the particle forms, while using acetone leads to relatively slower deformation rates that
cause fewer indentations and a deflated sphere morphology.
The hypothesis that crumpled particle morphology correlates with cosolvent
solubility with water is not supported by the methanol data. Indeed, methanol is more
soluble in water than ethanol or acetone. Furthermore, the difference in water solubility is
actually greater between methanol and ethanol than ethanol and acetone (Table 3.3).
Despite this, particles made with methanol had less surface area compared to particles
made by ethanol, indicating they were less crumpled or there was a lower frequency of
droplets that crumpled. Thus, factors other than cosolvent miscibility with water must also
be important in determining particle morphology. We found that surface area correlates
with resveratrol content among the particles made with the three different cosolvents.
Particles made with ethanol had a resveratrol content of 65 μg/mg and a surface area of 1.2
2

m /g. Particles made with methanol contained 23% less resveratrol and had a
corresponding 25% decrease in surface area compared to the particles made with ethanol.
However, particles made with acetone contained 72% less resveratrol than those made with
ethanol but exhibited only a 40% decrease in surface area. We believe this data indicates
that some cosolvents are better at transporting and/or retaining resveratrol at the oil–water
interface at critical levels that support droplet deformation as it shrinks, with both ethanol
and acetone outperforming methanol in this regard.
Many of the nonspherical particles observed were greater than 20 μm in size,
ranging up to almost 50 μm. Potential biomedical applications for particles in this size
range include acting as a drug depot or acting as a matrix for cell attachment and growth.
PLG microspheres loaded with naltrexone have been FDA approved, and have an average
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diameter around 60 μm129. The naltrexone particles are smooth and spherical and provide
nearly a zero-order release profile over 4 weeks. It is established that particle morphology
impacts drug release70. While it is unknown how the morphologies produced herein would
impact drug release profiles, we expect that drug release would be increased (compared to
spherical particles with similar size and drug loading) due to increased surface area. It has
also been reported that 40 μm particles with wrinkled surfaces promote greater cell
adhesion, when used as matrices for fibroblast culture, compared to smooth particles64.
Thus, crumpled drug delivery depots might be leveraged to target cell populations in tissues
based on their propensity to adhere to the crumpled surface.
Intracellular delivery of bioactive factors is an important aspect of drug delivery,
especially when modulating the immune system130–133. While many of the nonspherical
particles produced herein are too large for endocytosis, we believe that the emulsion
conditions can be modified to produce smaller, nonspherical particles with ridges and flat
surfaces that might impact cell uptake and intracellular delivery of bioactive factors. For
example, decreasing polymer molecular weight and increasing homogenization speeds
produces smaller droplets that will condense into smaller particles58. However, it is
important to consider that the small particles were less likely to be crumpled or indented in
the present work. This was not surprising because smaller droplets have a smaller FvK
number and thus are more resistant to crumpling127. The resistance of small droplets to
crumpling has also been reported for Pickering emulsions, in which the droplet surface is
solid134. For thin, elastic shells with small FvK numbers, slow deformation rates were more
effective at producing indentations127. Thus, focusing on acetone as the cosolvent may be
a promising avenue to develop small, nonspherical particles for intracellular drug delivery.
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A final consideration is the effect of resveratrol delivery from the particle, since it
is required to modulate particle shape. When given orally, resveratrol has been found to be
an antioxidant23, anti-inflammatory23, or an exercise mimetic26. Resveratrol is available as
a supplement in pill form and high doses (150 mg, six times/day, for thirteen doses) were
well tolerated in a clinical trial28. In vitro, it is found that concentrations of 50–100 μM do
not induce toxicity while inducing lipid mobilization in adipocytes and downregulation of
inflammatory signaling in macrophages25,135. For comparison, if 1 mg of the highly
crumpled particles (resveratrol loading of 65 μg/mg) released their resveratrol content into
100 mL of water (or tissue) instantaneously, the concentration would be less than 3 μM.
Thus, while resveratrol toxicity would need to be investigated for each biological system
in which the particles were applied, we believe it is plausible the resveratrol would be well
tolerated and could possibly synergize with other drug payloads. In addition, resveratrol
can also act as a preservative and increases the stability of a-tocopherol encapsulated in
whey protein particles subjected to oxidizing conditions136. However, if resveratrol loading
is undesirable, our previous research demonstrates we can decrease loading by up to 60%
with a 1-minute ethanol wash68. How this wash affects the loading of other bioactive factors
will need to be carefully studied as we move this technology forward.
3.5. Conclusion
Addition of resveratrol, with the aid of a cosolvent, to an emulsion of
dichloromethane and poly(lactide-co-glycolide) in aqueous polyvinyl alcohol leads to the
production of nonspherical particles following solvent extraction. Particle shape can be
modulated by cosolvent type with ethanol yielding highly crumpled particles and acetone
leading to particles that resemble deflated spheres. In addition, spherical particles can be
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obtained if ethyl acetate is used in lieu of dichloromethane and a cosolvent. The method
extends to polycaprolactone and poly(l-lactic acid) and is compatible with the
encapsulation of a hydrophobic fluorescent dye, suggesting hydrophobic bioactive agents
could be encapsulated. Video microscopy revealed that oil droplets crumple as they
decrease in volume during solvent extraction when resveratrol and ethanol were present.
Crumpling did not occur when droplets contained ethanol without resveratrol and geometry
remained spherical until the particles formed. This crumpling behavior is similar to when
a thin elastic shell is deformed and suggests that the surface of the droplets containing
ethanol and resveratrol may not be sufficiently fluid to maintain a spherical morphology as
the droplet decreases in volume. Resveratrol’s hydroxyl groups appear to be optimally
positioned to induce the nonspherical particles because the crumpling is lost with the
removal of the 4′ hydroxyl group or the addition of a 3′ hydroxyl group. Based on all the
data, we propose that resveratrol inhibits chain motion of polymers at the droplet’s surface
that must reorganize in order to maintain a spherical geometry and the function of the
cosolvent is to redistribute resveratrol from the droplet’s bulk to its surface. To our
knowledge, no other studies have reported production of crumpled or highly deformed
spherical particles using the oil in water emulsion/solvent extraction technique. Since
particle morphology impacts drug release kinetics and how biological systems engage with
a biomaterial, this method could be used to fine-tune FDA approved polymer-based
controlled release therapies already on the market or enable the development of novel
particle-based systems to control or study cell biology.
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CHAPTER 4
DEVELOPMENT OF MODIFIED PVA FOR SURFACE
FUNCTIONALIZING PLG MICROPARTICLES FOR MACROPHAGE
TARGETING AND SIGNALING3

4.1 Introduction
Macrophages are professional phagocytes that exist throughout the body. They
perform a wide variety of tasks, from phagocytic removal of pathogens to regulating
homeostasis14. There are many activated states of macrophages, however, it is traditionally
thought that they exist on a spectrum of phenotypes, from pro-inflammatory (M1) to antiinflammatory (M2)17. M1 phenotype is triggered in response to an infection and M2
phenotype is triggered when wound healing is needed. Macrophages play an important role
in many inflammatory diseases, and strategies that seek to “reprogram” their phenotype to
address an inflammatory disease have gained interest over recent years16.
Mannose receptor (MR) is a c-type lectin found primarily on macrophages and
dendritic cells and has recently been considered a target for inducing anti-inflammatory
(M2) phenotype in macrophages20,137. Although traditionally known as a phagocytic
receptor activated by pathogens, mannose receptor is not associated with the inflammatory

3
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response that other pattern recognition receptors have, such as toll-like receptor 4138. In
fact, it was found that mannose-capped lipoarabinomannan (a polymer of mannose) could
upregulate the nuclear receptor PPAR gamma in macrophages, which is thought to inhibit
inflammatory signals139,140. Another study found that clustering of the mannose receptor
via konjac glucomannan nanoparticles could induce an M2 phenotype, specifically
upregulating IL-10 production21, once again suggesting the anti-inflammatory nature of
MR. Despite these promising results, few other studies have looked at activating MR to
induce anti-inflammation in macrophages, and none to our knowledge have used
components in FDA approved particle systems such as the O/W emulsion process. Hence
strategies that aim to activate mannose receptor with mannose decorated particles made
with the O/W emulsion process could have promise in treating inflammatory diseases.
Previous groups have functionalized particles for macrophage targeting79,141,142.
None of these groups used PLG microparticles, however. PLG microparticles are excellent
candidates for delivery of mannose to MR on macrophages because PLG has a track record
of FDA approval, the emulsion fabrication process is well suited for making particles
around 2-3 microns and can be scaled for pharmaceutical production44. We hypothesize
that polylactide-co-glycolide (PLG) microparticles can be surface functionalized with
mannose and these particles can bind the mannose receptor to promote anti-inflammatory
effects in macrophages.
The oil in water (O/W) single emulsion solvent extraction process is the most
widely used for fabricating PLG microparticles52,58. Poly(vinyl alcohol) (PVA) is the most
common emulsifier used, and it ends up coating the surface of the particle after it is freeze
dried 74. We propose that conjugating molecules to PVA used in the emulsion process is a
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convenient strategy for functionalizing the surface of particles, as it allows for easy
characterization and PVA inserts on the surface of particles spontaneously during particle
formation74. This approach, to our knowledge has not been applied in studies by other
groups.
Isothiocyanates have traditionally been used in biomaterials to functionalize
proteins or other materials with abundant amine groups, however, isothiocyanates also
react with alcohols, such as PVA106. In the present study, we sought to test the
isothiocyanates that could be used to react with PVA to produce bioactive effects in vitro.
Herein, we developed PVA modified with fluorescein isothiocyanate (FITC), rhodamine
isothiocyanate (RITC), and mannopyranosyl phenyl isothiocyanate (MITC).
Attaching mannose in particular to the surface of particles could have implications
in many inflammatory diseases, and we predicted it could have implications for muscle
atrophy due to activation of the mannose receptor producing anti-inflammatory responses.
Muscle atrophy is the loss of muscle in response to a disease, disuse or simply aging9.
Sarcopenia specifically, which is muscle atrophy that results from aging, was estimated to
cost the U.S. $40 billion alone in hospitalizations in 2014143.

Muscle atrophy is

characterized by a decrease in muscle fiber size, and often coincides with an increase in
inflammation12. Targeting macrophages and inducing an anti-inflammatory and proregenerative phenotype is therefore an appealing strategy for treating muscle atrophy. Here,
we test the ability of mannose decorated (MITC) particles to bind to macrophages and
colocalize with the mannose receptor compared to particles without mannose. As a measure
of muscle growth, we test the ability of media conditioned with macrophages treated with
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MITC particles to increase the formation of C2C12 myotubes, the building blocks of
muscle tissue fibers.
4.2 Materials and Methods
4.2.1 Materials
50:50 poly (D,L-lactide-co-glycolide) (PLG) with an ester end group and a MW of
7,000-17,000 were purchased from Evonik (Birmingham, AL). Poly (vinyl alcohol) (PVA)
(MW 13,000–23,000, 87–89% hydrolyzed), dichloromethane (DCM), coumarin 6, and
fluorescein isothiocyanate isomer 1 (FITC) were purchased from Sigma (St. Louis, MO).
Rhodamine b isothiocyanate (RITC) was purchased from Cayman. Ethanol (ETOH) was
purchased from Decon Laboratories (King of Prussia, PA). Dimethyl sulfoxide (DMSO)
was purchased from Fisher (Hampton, NH). Ultrapure water was obtained from a Thermo
Scientific Barnstead Nanopure system. RAW 264.7 macrophages and C2C12 myoblasts
were obtained from ATCC (TIB-71) (CRL-1772). Dulbecco’s Modified Eagle’s Medium
(DMEM) with 4.5 g/L glucose and L-glutamine was purchased from Corning Cellgro
(Corning, NY). Trypsin with 0.25% EDTA, Fetal Bovine Serum (FBS) and Pen/Strep were
purchased from Fisher (Hampton, NH).
4.2.2 Modified Poly (Vinyl Alcohol) Synthesis
Modified PVA was prepared by dissolving 100 mg of PVA into 10mL of DMSO
along with an amount of the isothiocyanate molecule (fluorescein isothiocyanate,
rhodamine isothiocyanate or mannopyranosyl phenyl isothiocyanate) that corresponded to
a mole percentage of OH groups present on the backbone of the polymer (0.1, 1 and 10%
for example). This mixture was reacted at varying times from 5-24 hours and varying
temperatures from 25°C to 80°C as listed in Table 4.1. After reaction, the modified PVA
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was added to dialysis tubing with 3.5 kDa MWCO and allowed to dialyze for 3 days in 5L
of ultrapure water, with exchanges of water twice a day. After this, the PVA product was
frozen and lyophilized overnight. Final dried product was weighed, and mass yield was
calculated via equation 1:
𝑀𝐼𝑇𝐶−𝑃𝑉𝐴

𝑀𝑎𝑠𝑠 𝑌𝑖𝑒𝑙𝑑 (%) = (𝑀

𝑃𝑉𝐴 +𝑀𝐼𝑇𝐶

) ∗ 100

(1)

Where MITC-PVA is the final mass of modified PVA, MPVA is the initial mass of PVA and
MITC is the initial mass of isothiocyanate.
4.2.3 Fourier Transform Infrared Spectroscopy
FTIR of PVA and modified PVA was collected on a PerkinElmer Spectrum 100
machine. About 5 mg of sample was spread on the sample holder and data recorded from
650-4000 cm-1. Transmittance was plotted against wavenumber (cm-1). Peaks were
analyzed qualitatively.
4.2.4 Nuclear Magnetic Resonance Characterization
H-NMR of PVA and modified PVA was carried out using a Bruker Avance IIIHD
400 MHz spectrometer. 10 mg of samples were dissolved in 0.7 mL of DMSO-d6. 32 scans
were taken with a 20ppm window centered at 6.175 ppm. 4 second acquisition time with 1
second recovery delay and 30-degree pulse widths was used.
4.2.5 Polymer Particle Fabrication
Polymer particles were prepared using a single oil-in-water emulsification solvent
extraction method. Briefly, 50:50 PLG was dissolved in dichloromethane at a concentration
that would achieve a final organic phase concentration of 4% (wt/wt). For the emulsion,
0.6 mL of organic phase was added dropwise into 4 mL of an aqueous solution of 0.2%
(wt/v) polyvinyl alcohol (PVA) or modified PVA, and homogenized at 11000rpm for 5
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minutes using a Kinematica PT3100D homogenizer. Solvent extraction was then
conducted by adding the emulsion to 80 mL of ultrapure water and then stirring the mixture
for 1 hour. This allowed the dichloromethane to extract and evaporate and the resulting
particles to harden. The particles were then passed through a 40 µm filter (Greiner Bioone), collected via centrifugation at 250xg (to collect particles 2 µm and larger) and washed
4 times in ultrapure water. Washed particles were frozen at -20°C and subsequently
lyophilized overnight with a Labconco freeze dryer. Recovered particles were stored under
vacuum in a dry environment at room temperature. For coumarin 6 loaded particles, all
conditions were the same except coumarin 6 was added to the organic phase at 0.3 mg/mL.
4.2.6 Light Microscopy (LM)
Light and epifluorescence microscopy images of particles were taken on an EVOS
FL microscope at 20x magnification. Particles were prepared in ultrapure water and
suspended at a concentration of 0.25 mg/mL. 400 µL of these suspensions was added to a
well of a 48-well plate and allowed to settle prior to image acquisition. Fluorescence
images were taken on the green GFP (470nm) or red RFP (560nm) fluorescence settings.
4.2.7 Particle Size Measurements
Particle size was found by analyzing light microscopy images using ImageJ
software. Briefly, three representative images were taken of each particle condition and
converted to binary (B/W) colors. The Particle Analysis plugin in ImageJ was used to
measure particle diameter. We report the mean particle diameter and the coefficient of
variation (CV%), which is the standard deviation divided by the mean. We validated this
method previously by accurately measuring the size of purchased polystyrene beads68.
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4.2.8 Mass Yield
Mass yield was calculated by dividing the mass of recovered particles by the mass
of polymer and resveratrol emulsified. Particle mass yield was calculated according to
equation 2.
𝑀𝑎𝑠𝑠 𝑌𝑖𝑒𝑙𝑑 (%) = (𝑀

𝑀𝑃𝑇

𝑃𝑜𝑙 +𝑀𝑅𝐸

) ∗ 100

(2)

Where MPT is the mass of particles recovered from the emulsion, MPol is the mass of
polymer added to the emulsion, and MRE is the mass of resveratrol added to the emulsion.
4.2.9 Cell Culture
RAW 264.7 macrophages (ATCC TIB-71) were subcultured via the ATCC
protocol. Briefly, cells were seeded at 625,000 cells in T-25 flasks in 3 mL of complete
media (DMEM supplemented with 1mM sodium pyruvate, 1500 mg/mL sodium
bicarbonate, 1% penicillin-streptomycin, and 10% fetal bovine serum). This was allowed
to grow for 2 days or until cells became about 60-70% confluent. Cells were then rinsed
with PBS and 1 mL of Trypsin with 0.25% EDTA was added for 5 minutes at 37°C. Trypsin
was then diluted into 2 mL of complete media, cells were scraped with a rubber policeman
and added to a 15 mL centrifuge tube. An aliquot of this solution is diluted with Trypan
blue and used to count the cells with a hemacytometer. The rest is centrifuged at 1500 rpm
for 5 minutes. The cell pellet is reconstituted in complete media and seeded into flasks and
plates as needed. Cells were seeded at 25,000/cm2.
C2C12 myoblasts (ATCC CRL-1772) were subcultured via the ATCC protocol.
Cells were seeded into T-25 flasks at 125,000 in 3mL of complete media (DMEM
supplemented with 1% penicillin-streptomycin and 10% fetal bovine serum). When cells
were 60-70% confluent, they were rinsed with PBS and 1 mL of trypsin was added for 5
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minutes at 37C. Trypsin was diluted into 2 mL of complete media and cells were collected
into a 15 mL centrifuge tube. Cells were counted as described above and centrifuged at
1500 rpm for minutes. Cell pellet was reconstituted in complete media and seeded into
flasks and plates as needed.
4.2.10 Particle Binding Assay
RAW 264.7 macrophages were cooled to 4°C and then incubated with coumarin 6containing MITC or blank particles for 10, 20 and 30 minutes at 0.3, 1.5 and 3 µg per well.
Unbound particles were then washed away with ice cold PBS. To visualize particle binding
in situ, cells were fixed in 10% Formalin, stained with Hoescht at a 1:2000 dilution and
imaged with a EVOS fluorescent microscope. To quantify particle binding, cells were not
fixed, but incubated with DMSO to solubilize the bound coumarin 6 particles. The DMSO
was then collected and added to a 96 well plate. Fluorescence in the DMSO was measured
in a black 96 well plate with a Biotek plate reader. A serial dilution of fluorescent particles
was made in DMSO to make a standard curve of fluorescent intensity vs µg/mL of particles
dissolved. This resulted in a linear relationship shown in equation 3.
µg

𝐹𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 = m ∗ (mL 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠) + 𝑏

(3)

Where m is the slope and b is the y intercept of the linear regression. Concentration
of particles (µg/mL) bound was calculated by interpolating the standard curve and mass of
particles bound was calculated by multiplying by the volume (mL) of DMSO used to
extract the particles (0.1mL).
4.2.11 Mannose Receptor Colocalization
Colocalization of MR in macrophages was studied in response to particle treatment.
RAW 264.7 cells were cultured as described above and cells were seeded in 24 well plates.
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Particles were added 24 hours later at a 1:10 cell:particle ratio. Particles were incubated for
3 hours at 37°C. Cells were washed thoroughly 3 times in PBS. Cells were fixed in 10%
formalin for 30 minutes. Blocking was done in 1% BSA for 1 hour and cells washed twice
in PBS. MR antibody (Abcam) was added at 10 µg/mL for 1 hour at RT and cells washed
twice in 1% BSA in PBS. Secondary antibody (Alexa Fluor 555) was added at 8 µg/mL
for 1 hour at RT and cells washed twice in 1% BSA in PBS. Hoescht was added at 1:2000
dilution for 5 minutes. Cells were imaged on an EVOS FL microscope on the DAPI, GFP
and RFP settings. Quantification of colocalization was done in ImageJ. Green and red color
were thresholded. Yellow color was set to the hue range of 15-58 in ImageJ. Area of green
and area of yellow were analyzed and the yellow area divided by the green area was
calculated. Conditions used were: cells only, cells treated with blank particles and cells
treated with MITC particles.
4.2.12 RAW 264.7 Conditioned Media on C2C12 Myoblast Differentiation
RAW cells were seeded in T-25 flasks at 25,000 cells/cm2 on day 0 and particles
added on day 1. On day 2, conditioned media was collected and frozen. C2C12 cells were
plated at 5,000/cm2 and differentiation began on day 1. Conditioned media in a 50:50 ratio
with differentiation media was added on day 2, 3 and 4. On day 5, myotubes were fixed
with formalin for 30 min and blocked in 10% goat serum with 0.3% Triton X. Then,
Myosin Heavy Chain primary antibody was added at 10 µg/mL for 1 hour. Next, Alexa
Fluor 555 secondary antibody was added at 1:200 dilution for 1 hour. Cells were
counterstained with Hoescht at 1:2000 dilution for 5 minutes. Cells were then imaged on
the RFP channel on an EVOS FL microscope. Number of nuclei per myotube per frame
for three independent wells were counted with imageJ. Myotubes counted were set as
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having more than 3, 6, or 9 nuclei to demonstrate three different ways of defining
myotubes.
4.2.13 Statistics
Prism graphpad software was used to carry out statistical analysis. Error bars
represent standard deviation. Where appropriate, unpaired t-test, one-way ANOVA and
two-way ANOVA with Tukey’s multiple comparison test were used to compare
differences in the means. P<0.05 was used as an indication of statistical significance.
4.3 Results
4.3.1 Synthesis of Modified PVA
FITC, RITC and MITC modified PVA was synthesized via a one-step reaction as
shown in Figure 4.1A. The reaction proceeded in DMSO for 5-24 hours at varying
temperatures, and after 3 days of dialysis the modified PVA was recovered via
lyophilization, seen in Figure 4.1B. FITC was added at 0.1, 1 and 10% by mol OH group
and RITC was added at 1% by mol OH group. The recovered products were colored as can
be seen in Figure 4.1C, suggesting a successful reaction of the components. We ran 16
trials of modified PVA reactions seen in Table 4.1. We varied the ITC group, the ITC mol
% added, the reaction time, the temperature, and the solvent used, and the mass yield was
measured by weighing the product. The % OH conjugated by running NMR analysis.
4.3.2 Characterizing FITC modified PVA.
FITC modified PVA was characterized with FTIR and NMR shown in Figure 4.3.
FTIR of PVA showed the characteristic OH peak around 3350 cm which was not present
in the FITC (Figure 4.2A). FTIR of FITC alone showed the characteristic cyano (NCS)
peak around 2000, which was not present in the PVA and notably not in the FITC-PVA,
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Figure 4.1. Synthesis of Modified PVA. A) Isothiocyanate (ITC) modifiers were
attached to PVA via a one-step reaction. B) PVA and ITC were added to DMSO for 5
hours at room temperature and then dialyzed against water in tubing with MWCO of
3.5 kDa. C) Images showing FITC modified PVA at 0.1, 1 and 10% by mol OH
conjugation and RITC modified PVA at 1% by mol OH conjugation.

Table 4.1. Reaction trials of ITC modifiers with PVA

ITC

ITC
%

Rxn
Time

Temp

Solvent

Mass
yield

1

FITC

0.1%

5 hr

RT

DMSO

37%

% OH
conjugated
(from
NMR)
0

2

FITC

1%

5 hr

RT

DMSO

29%

0.07

7%

3

FITC

10%

5 hr

RT

DMSO

25%

8

80%

4

MITC

1%

5 hr

RT

DMSO

51%

0.11

11%

5

MITC

10%

5 hr

RT

DMSO

55%

0.13

1.3%

6

MITC

20%

5 hr

RT

DMSO

19%

0.16

0.8%

Trial
#
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conversion
0%

7

MITC

5%

24 hr

RT

DMSO

46%

0

0%

8

MITC

5%

24 hr

RT

DMSO/H2O

53%

0

0%

9

MITC

5%

24 hr

60C

DMSO

54%

0.19

3.8%

10

MITC

5%

24 hr

60C

DMSO/H2O

66%

0.08

1.6%

11

MITC

5%

5 hr

60C

DMSO

36%

0.05

1.0%

12

MITC

5%

24 hr

80C

DMSO

21%

1.7

34%

13

MITC

5%

24 hr

80C

DMSO

28%

0.87

17.4%

14

MITC

5%

24 hr

80C

DMSO

28%

0.91

18.2%

15

MITC

5%

24 hr

100C

DMSO

34%

1.3

26%

16

MITC

5%

24 hr

100C

DMSO

28%

1.03

21%

17

RITC

1%

5 hr

25C

DMSO

35%

0.4%

40%

suggesting a successful reaction, because a monothiourethane bond should replace the
isothiocyanate bond. The FITC modified PVA had the 3350 OH peak and the 1600 C=C
peak seen in FITC, suggesting FITC had been attached. NMR characterization showed
PVA had proton peaks in the 2 ppm region, characteristic of the carbon backbone (Figure
4.2B). FITC spectra showed peaks in the 7-10 ppm region characteristic of the phenyl rings.
10% FITC-PVA (Table 4.1, Trial 3) contained both of these peaks, and integration of the
two showed a ratio of 24:200 which corresponded to 8% of the OH a conversion of 80%
of the FITC by mole. This data indicates that FITC attachment to PVA proceeds readily at
room temperature with high conversions of 80%.
4.3.3. Characterizing MITC modified PVA
MITC was reacted with PVA in the same manner as FITC and RITC. Initially, we
found 0% conversion of MITC with PVA, which was surprising because 80% conversion
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Figure 4.2. Characterization of FITC-PVA. A) FITC modified PVA (green), PVA
(red), and FITC (blue) were analyzed with FTIR spectroscopy. Carbonyl shift at 1600
was highlighted in green representing the carbonyl present on the FITC molecule
(circled in green). B) NMR spectra of FITC-PVA, PVA and FITC. Characteristic
protons in FITC and PVA are marked with a and b respectively and labeled on the inset
structure. Integration of these two peaks suggested 80% conversion of FITC.
was found with FITC. It was found that increasing the temperature of the reaction bath
increased the conversion of MITC, suggesting a temperature dependence, seen in Table 4.1
and Figure 4.3B. Figure 4.3A is an NMR spectra of PVA, MITC and MITC PVA from
Trial 15 in Table 4.1. MITC was characterized similarly to FITC, phenyl protons were
compared to PVA backbone protons.

84

Figure 4.3. Characterization of MITC-PVA. A) NMR spectra of MITC-PVA (green),
PVA (red) and MITC (blue). Characteristic protons of MITC and PVA are labeled with
a and b respectively. B) Plot of MITC conversion vs. temperature for 5 different
reaction trials from Table 4.1.

4.3

PLG particle fabrication
Microparticles were fabricated using an oil in water single emulsion as previously

described, shown graphically in Figure 4.4A. Fabrication parameters such as
homogenization and centrifugation speed were optimized previously71 to make particles
with diameters of 2-4 µm and low polydispersity. FITC-labeled PLG particles were
imaged under confocal microscopy and cross-section z-slices of the particles showed a ring
around the particles, demonstrating visually that the fluorescent PVA was coating the
surface of (Figure 4.4B). Similarly, RITC-labeled PVA particles had red signal under
epifluorescence microscopy, showing solid circles instead of rings due to the fact that all
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of the z-direction was collected (Figure 4.4B). Particles were also imaged under bright field
microscopy seen in Figure 4.4C. Particle diameter was 3.5 µm for blank, 3.7 µm for FITC,
3.7 µm for RITC, and 2.8 µm for MITC. Epifluourescent images of particles loaded with
coumarin 6 are shown in Figure 4.4D. Coefficient of variation (CV) was less than 40% for
all conditions, indicating low polydispersity. Mass yield varied between 40% and 60% for
all conditions without a clear trend. MITC-PVA, PVA, MITC-PVA C6 and PVA C6
particles were used for future cell studies.
4.3.5 Cold binding of particles with macrophages
RAW 264.7 cells were treated with blank and MITC particles loaded with coumarin
6 at 0.3, 1.5 and 3 µg per well for 10, 20, and 30 min at 4°C. Wells were washed with PBS
three times, DMSO was added to each well and fluorescence was quantified. Mass bound
was calculated from a standard curve of coumarin 6 particles and was plotted against time
for each dose as seen in Figure 4.5. We found that MITC significantly increased the mass
of particles bound at the 0.3 µg dose, but not at 1.5 µg. At 3 µg dose MITC increased
binding at 20 min but not at 10 or 30 min. This confirms that particles were successfully
functionalized with mannose and have bioactive effects with macrophages. This data also
suggests that it may be important for mannose functionalized particles to be used at low
concentrations.
4.3.6 MITC particles are more associated with mannose receptor
RAW 264.7 macrophages were treated with 3 µg MITC C6 and blank C6 particles
(No MITC) for 3 hours at 37°C and were fixed and stained with MR antibody and
counterstained with Hoescht. As seen in Figure 4.6, MR (red) was well expressed
throughout the cells in all conditions. In untreated cells (Figure 4.6A) there were distinct
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Figure 4.4. Imaging of PLG particles made with modified PVA. A) Diagram of O/W
emulsion process for PLG particles. B) Confocal image of FITC-labeled PLG particles
and Epifluorescent image of RITC-labeled PLG particles. C) Bright field images of
modified PVA particles and D) Epifluorescent images of coumarin-6 loaded particles.

regions high in MR spread throughout the cell. Blank and MITC particles were readily
taken up by macrophages (Figure 4.6B and C). MITC particles appear visually to colocalize
with the MR stain to a greater extent than blank particles, suggesting receptor binding was
occurring. Quantification of colocalization via ImageJ suggesting MITC was having an
effect as well, with a p value of 0.0568 (Figure 4.6D).
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Figure 4.5. Binding of MITC particles by RAW cells. RAW 264.7 cells were treated
with blank and MITC particles for 10, 20, and 30 minutes at 3 doses: 0.3 (A) 1.5 (B)
and 3 µg (C) of particles. Particles were loaded with coumarin 6, and at each timepoint
cells were washed 3x with PBS and DMSO was added to the well to extract the
coumarin 6 dye. Mass bound was quantified by reading the fluorescence of each well
on a plate reader and comparing to a standard curve of coumarin 6 loaded particles.
Data was analyzed with a Two Way ANOVA, and * = p<0.05, ** = p<0.01 in the Blank
vs MITC comparison for each condition with a multiple comparisons test. Error bars
are standard deviation.
4.3.7 Macrophage conditioned media affects myotube formation
RAW cells were treated with particles for 24 hours. Media was collected and mixed
50:50 with C2C12 differentiation media and C2C12 myoblasts were treated with this
“conditioned” media for 3 days. On the fourth day, C2C12 cells were fixed and stained
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Figure 4.6. Colocalization of MR with MITC-PVA particles. Raw 264.7
cells were treated with A) no particles, B) blank particles and C) MITC
particles for 3 hours. D) Quantification of the percentage of particles with
yellow colocalization by area. Data was analyzed with an unpaired t-test.
with myosin heavy chain, a marker for myotube formation. As seen in Figure 4.7A, multinucleated myotubes were stained with myosin heavy chain, and undifferentiated cells were
not. Cells treated with media only (Figure 4.7A media) were short and did not have many
nuclei, whereas cells treated with macrophage conditioned media appeared larger and had
more nuclei. Myotubes treated with particle conditioned media appeared larger, and
myotubes treated with macrophage+particle treated media appeared largest. Indeed,
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Figure 4.7. Effect of macrophage and particle conditioned media on myotube
formation. A) Myotubes treated with media alone, media conditioned with MITC-PVA
particles, media conditioned with macrophages and media conditioned with
macrophages treated with MITC-PVA were stained with myosin heavy chain seen in
the red channel of an EVOS FL microscope. B) Quantification of the number of
myotubes per well per frame with greater than 3, 6 and 9 nuclei. One-way ANOVA was
conducted with a Tukey’s multiple comparisons test where * = p<0.05, ** = p<0.01,
*** = p<0.001,
quantification of the number of nuclei per myotube per frame confirmed these trends
(Figure 4.7B). Quantifying myotubes set at having greater than 9 nuclei revealed that MITC
particle treated macrophage media had a statistically significant increase compared to
macrophage media treated alone.
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4.4 Discussion
In this study we find that PVA can be modified with three different isothiocyanate
derivatives. In RAW 264.7 macrophages, mannose modified PVA particles bind to the
surface and colocalize with MR to a higher extent than do particles without mannose. In
addition, media conditioned with macrophages treated with mannose modified PVA
particles promote myotube formation.
An important area of research in polymer particle design is surface functionality.
Many methods for surface functionalization have been shown in the literature, including
passively adsorbing ligands to the surface of particles, conjugating ligands to PVA using
EDC, NHS, and CDI chemistry, and PEGylation59,66. After particles are formed,
characterization can be a challenge. An approach that would be useful is conjugating and
characterizing the product prior to particle formation. To that end, we proposed that PVA
could be modified, characterized, and then localized to the surface of polymer particles
during the O/W emulsion process. Here we show that PVA can be modified with
isothiocyanate

chemistry

with

three

different

isothiocyanate

derivatives,

and

characterization can be completed prior to particle formation.
The three isothiocyanate derivates were first tested at 25°C for 5 hours. 10% FITCPVA had highest conversion (80% conversion) as measured by NMR and MITC had the
lowest conversion at 25C at 0%. Interestingly, MITC conversion was temperature
dependent, and required increasing temperature to 100°C to achieve higher conversion.
This may be because of the more hydrophilic nature of MITC being less soluble in DMSO.
We achieved 1.3% OH conjugation at 100°C reacting for 24 hours for a conversion of 26%.
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In this study FITC and RITC-PVA coated the surface of 50:50 low MW PLG
particles and could be visualized under confocal and epifluorescent microscopy. Particles
formed were between 2-4 microns with relatively low dispersity (CV<40%). Rings seen
under confocal microscopy confirm that PVA is localized on the surface of particles. ITCmodified PVA was shown to coat the surface of particles via microscopy, and was
conjugated to PVA to a high extent, however, we sought to demonstrate bioactive effects
with mannose decorated particles by affecting macrophages in vitro.
In a cold binding study, MITC particles bound macrophages to a higher extent than
blank particles. This only occurred at the low particle dose (0.3 µg). One reason that only
low doses increased binding may be that higher doses promote more nonspecific binding,
thus reducing any effect seen by MITC. Low doses of particles may also be more clinically
relevant, because as particles get administered in the body it is likely only low numbers of
particles will interact with each cell. As a point of comparison, one study showed that
mannose coated particles improved binding compared to blank particles, however, this only
occurred when the particles were capped with a methoxy and not a hydroxyl142. They
suggested that hydroxy binds more readily than methoxy. PLG particles are coated with
PVA hydroxyl groups, and this could be why blank particles bind to a high extent and no
effects are seen at high particle doses. Blank particles may also bind other receptors, such
as TLR4.
At 3 µg dose and at 37C MITC particles were found to colocalize to a higher extent
than blank particles with RAW 264.7 macrophages. This suggested to us that mannose
decorated particles had functional effects and were associating with MR as we predicted.
A previous study showed that nanoparticles induced “nanoclusters” of MR could be
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produced upon treatment with mannan functionalized nanoparticles21. In the present study
particle signal and MR signal colocalized, and although “nanoclusters” were not observed,
we cannot rule out that a similar clustering effect was occurring.
To demonstrate that MITC particles were converting macrophages into an antiinflammatory phenotype, we treated macrophages with particles, then treated
differentiating C2C12 myoblasts with macrophage conditioned media. We show myotubes
induced with MITC particles treated macrophage media had more nuclei than myotubes
treated with just macrophage media. This suggested that MITC particles were inducing a
change in the secretome of macrophages that was favorable to myotube formation.
Macrophages produce many factors that could be beneficial to myotube formation, such as
IL-10, TGF-beta, PDGF, and IGF-114. Future studies will be conducted to determine which
of these factors, or other factors could be producing this increase in myotube formation
4.5 Conclusion
This study demonstrates that isothiocyanate chemistry can be used to functionalize
PVA, that it can be used to coat PLG particles and can have therapeutic benefits in terms
of muscle atrophy. Three isothiocyanate derivatives, FITC, RITC and MITC were attached
to PVA at high concentrations. MITC reaction was temperature dependent, with a high
conversion achieved at 100°C. Particles were successfully coated with modified PVA as
evidenced by fluorescent microscopy and by MITC binding of macrophages. In addition,
MITC particles colocalized with MR in macrophages and induced myotube formation in
macrophage conditioned media. Taken together, this data suggests that this one-step
reaction for attaching ligands to PLG particles could be useful in many instances where
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ligand attachment is needed, and PLG particles decorated in mannose in this way can have
positive implications for the treatment of muscle atrophy.

94

CHAPTER 5
CONCLUDING REMARKS AND FUTURE DIRECTIONS
5.1 Concluding Remarks
Biodegradable polymer particles have proven incredibly useful for treating a
variety of diseases over the last few decades, as evidenced by the number of particle
formulations that have been FDA approved and rise in number of publications this field
has generated33. However, more research is still needed into the field of O/W emulsions
for polymer microparticle fabrication continue to achieve more FDA approvals. Although
the O/W emulsion system is simple conceptually, it has many parameters that affect
response variables and achieving consistent manufacturing has been a challenge. In
addition, many inflammatory diseases may benefit from polymer particle drug delivery,
however, some avenues of investigation, such as resveratrol and mannose incorporation
into polymer particles, require more research. The objective of this dissertation was to test
the effects of incorporating the polyphenol resveratrol and the sugar mannose into the
particle design for treatment of inflammatory diseases, and to better understand the effects
of fabrication parameters on response variables such as morphology and surface
functionality.
In Chapter 2 it was shown that resveratrol could be incorporated effectively into
PLG microparticles. Resveratrol encapsulation required the addition of ethanol as
cosolvent in the system, and resulted in nonspherical particle morphology, as demonstrated
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by SEM imaging. These resveratrol particles induced lipolysis as shown by an oil red o
assay on 3T3-L1 adipocytes, suggesting potential of these particles as an anti-obesity
formulation. The nonspherical particles showed sustained resveratrol release over 42 days,
however, the release was somewhat variable. It was determined that resveratrol particle
size was controlled by homogenization time and speed. Smaller particles made with less
resveratrol had more uniform release profiles. A major finding was that resveratrol was
surface loaded. This was demonstrated by the higher burst release of smaller particles, the
higher removal of resveratrol by ethanol of smaller particles, and the disruption of FITCPVA signal by resveratrol under confocal microscopy. The implication of resveratrol being
surface loaded is important in designing drug delivery systems. Longer release applications
would require larger particles such as those with a 10-micron diameter or larger because
we demonstrated there is a lower burst release. Evidence of surface loading and
nonspherical morphology of resveratrol particles led to studies of the mechanism of
nonspherical particle formation.
As a result of the finding that resveratrol caused nonspherical morphology in PLG
particles in Chapter 2, we set about understanding this effect further. Studies on the
morphology change suggested it was dependent on PVA concentration in the aqueous
phase and resveratrol concentration. In Chapter 3, light microscopy videos of particle
formation demonstrate that PLG particles crumple during the formation process. The
videos suggested that a shell was forming around particles and as the solvent was removed
the shell was collapsing. In addition, it was found that nonspherical morphology of particles
was dependent on cosolvent selection and concentration of cosolvent in the organic phase.
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This led to the conclusion that resveratrol was surface active. In fact, other stilbene
molecules did not convey the same morphology change; it was unique to resveratrol.
Surface functionality is another parameter of interest in fabrication of polymer
microparticles. There have been many efforts to functionalize the surface of polymer
particles in the literature. In particular, NHS, EDC, CDI chemistry have been used
previously72, which have all shown very promising results in many articles as efficient
methods for attaching ligands. In this dissertation a novel approach was taken to
functionalize the surface of PLG particles, i.e. modification of PVA. Modifying the PVA
which coats the surface of particles to provide surface functionality was discussed in
Chapters 2 and 4. Isothiocyanate chemistry was used to attach FITC, RITC and MITC on
to PVA. Being fluorophores, FITC and RITC attachment provided fluorescent
visualization of PVA, and acted as a fluorescent tag for PVA via microscopy. This was
demonstrated in Chapter 2 when resveratrol interactions with PVA could be visualized
through decreases in PVA signal in confocal microscopy.
In Chapter 4, it was demonstrated that MITC attachment to PVA provided bioactive
functionality to PLG particles. This was demonstrated through particle binding at 4°C,
through colocalization of particles with MR at 37C and through MITC particle inducing
macrophage secretory activity that promoted myotube formation. The premise of this
therapy would be that injection of mannose-decorated particles into muscle would work by
inducing secretion of muscle-regenerative factors from macrophages. These results
demonstrated that modifying PVA for surface functionalization is not only useful for
determining surface characteristics of particles but also as a method for achieving bioactive
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effects in cells. We propose that our modified PVA method is a simpler method of surface
ligand attachment than other chemistries currently used in the literature.
Taken together, the results of this dissertation provide several main innovations to
the polymer microparticle field. Namely: i) a potential microparticle system for the delivery
of resveratrol for the treatment of obesity, ii) a simple method for tuning morphology of
polymer microparticles by adding resveratrol in O/W emulsion solvent extraction systems,
ii) a new method for functionalizing the surface of polymer particles made with the O/W
emulsion solvent extraction method by modifying PVA with isothiocyanate chemistry, and
iv) using mannose decorated particles to target macrophages in treatment in muscle
atrophy. These innovations in understanding how components of the O/W emulsion solvent
extraction system affect surface properties could have far-reaching effects in the design of
new controlled release systems for FDA approval, and could have a direct impact on a
growing sector of the pharmaceutical industry.
5.2 Future Directions
The results of this dissertation indicate that particles created here show promise.
However, there is still work to be done to move the technology forward. Namely, i) using
resveratrol particles in mouse studies for the treatment of mice fed a high-fat diet, ii) seeing
how morphology of particles affect the performance in vivo, iii) attaching new ligands to
the surface of PLG particles, for example other sugar molecules beyond mannose, and iv)
testing mannose-presenting particles in mouse studies for the treatment of mice with
muscle atrophy.
In this work it was shown that resveratrol-loaded microparticles can be added to
adipocytes and promote lipid mobilization. Although other systems have added resveratrol
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to polymer particles144, it has not been shown previously that they can have these effects
on adipocytes. Because of these promising results, we predict that resveratrol particles can
decrease the fat mass of mice on a high-fat diet compared to blank particles. Future studies
should look at the effect of dose and time on fat mass and glucose tolerance in C57/BL6
mice fed a high-fat diet. The high-fat diet model for obesity has been used previously by
our lab, and could be implemented to test microparticle effects on mice145,146.
In this work we show that resveratrol causes nonspherical morphology upon
addition to the O/W emulsion solvent extraction method. Nonspherical morphology of
polymer microparticles has been shown before in the literature, but the innovation of our
system is that it requires only the addition of a natural compound (resveratrol) in the
emulsion system to achieve morphology changes. Future studies could look at how
“crumpled” and “deflated beach ball” particles shown in Chapter 3 compare to smooth
particles in the attachment to various cell types, such as fibroblast cells 64. It is possible
that increased interaction with target cells could increase the amount of drug that reaches
its destination. The implication here is that by simply adding resveratrol to an FDAapproved system could improve targeted delivery of the drug to cells of interest.
Design of modified PVA also has important implications in the drug delivery field.
Current methods for surface functionalization often involve complex chemistry applied to
particles post-fabrication. The method presented of modifying PVA pre-fabrication and
simply dissolving it in the aqueous phase to achieve particle surface functionality could be
applied to any molecule with an isothiocyanate group. Future studies should determine if
this technology is possible with other molecules useful in MR targeting such as fucose and
n-acetylglucosamine147. One important consideration for the results in Chapter 4 of this
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dissertation is that the PVA is decorated with mono-mannose, and it is possible that dimannose or tri-mannose would have stronger effects in vitro. In fact, the mannose receptor
responds more strongly to higher density mannose, such as the polymer mannan148. Future
studies should determine if conjugating PVA with di-mannose, tri-mannose or mannan
have a stronger effect than mono-mannose.
Collectively, the future directions suggested here could have impacts on the
usefulness of resveratrol particles to treat obesity and mannose-decorated particles to treat
muscle atrophy. The O/W emulsion solvent extraction system is a straightforward and
scalable process and is already used in FDA-approved systems. The results shown here can
easily be implemented in these systems by simply adding resveratrol to the oil phase or
modifying PVA used in the aqueous phase to have significant effects on particle properties.
The groundwork is laid here for future researchers to now implement these innovations
into new and improved biodegradable polymer microparticle systems.
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APPENDIX A
PLG PARTICLE FABRICATION BEST PRACTICES

PLG particle fabrication is a central technique used in the Gower lab. It is a
somewhat complicated process that can be very sensitive to small changes in the protocol.
One thing to keep in mind is that small things in the protocol (like vortexing the PLG
solution and evaporation time of the extraction bath) can actually have a big impact on the
final microparticle product. As such, I would like to include some tips and tricks I have
learned over the years. Li et al. 2008 is a great primer on this fabrication processs58. The
general PLG particle fabrication protocol is kept on the Gower lab drive, but what follows
are some additional considerations I would like to mention.
First, any particle fabrication may end up being used in cell culture or an animal
study. It is very important that aseptic conditions be used as much as possible. The
homogenizer is cleaned before and after fabrication as follows: 5 minutes in acetone, 5
minutes in ethanol, 5 minutes in water and 5 minutes in water at 11,00rpm. Use fresh clean
20 mL scintillation vials for dissolving PLG and drug in the organic phase. Keep vials and
centrifuge tubes closed and only open them in the hood when it is time to add what is inside
to the emulsion. When it is time to do the wash steps, bring the beakers into the laminar
flow hood. Filter and remove supernatant in there.
Second, quality of PVA is important. Make up a fresh PVA solution the day before
fabrication. Dissolving PVA in water requires heat and takes a while to dissolve, so give
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yourself a few hours for this process. Store PVA in the 4C refrigerator. I found that larger
concentrations of PVA (2-5 wt/v%) do not store for a long time, in other words the PVA
begins to precipitate out of solution after about a week. As a general rule, I would not use
PVA that is over a week old. If possible, use PVA the day after you make it to avoid this
issue. In terms of the concentration of PVA, it is not feasible to go higher than 5% wt/v
with the 18,000 Da PVA we use in the lab. It will not dissolve easily and will also
precipitate when it is cooled. Concentrations as low as 0.1% wt/v are feasible, but the
emulsion will begin to lose stability and the particle size distribution will increase at this
concentration.
Third, use new scintillation vials for every beaker of particles you make. I found
that making a stock solution of particles and dipping in for every emulsion resulted in
inconsistent mass yields and particle loading values. Make sure to vortex the vial right
before you add it to the emulsion. Also, use a fresh 40 um filter for each condition you are
doing during the wash step (you can re-use the filter for replicates of the same condition).
For washing the homogenizer use a glass slide jar and fill it with the solvents you
are using (there is a jar that is used just for particle fabrication washing). Wash the
homogenizer tip between fabrications of different conditions. This will prevent crosscontamination. Two washes for 30secs in acetone and one in water should be sufficient.
This cleans any residue off the tip and also prevents cross contamination.
Particle size is dependent on PLG concentration in the organic phase,
homogenization speed, and centrifugation speed. In particular, centrifugation speed can be
used to “purify” a size of interest. Slower speeds do not settle the smallest particles, and
you can “tighten” your size distribution by running at slower speeds to remove submicron

118

particles. This is a product of the stokes law for sedimentation which dictates that
sedimentation rate is dependent on particle size, density and viscosity of the medium
among several things. The speed to purify a certain size range is dependent on the
instrument used and the distance needed to settle (length of your centrifugation tube). For
example, in our system I found that 250xg settles 2 um particles efficiently when spun for
10 minutes in the large centrifuge in the basement lab (SWGN 0B9).
Homogenization speed can also control size, but I don’t recommend running the
homogenizer at speeds higher than 11,000 rpm. Higher speeds in our emulsion medium
made loud noises in the homogenizer. As a result, adjusting PLG concentration is the other
option for making different sizes. I found that it is not feasible to go to less than 1% wt/wt
(PLG/DCM) in the system for two reasons. One is the mass yield is too low to be usable.
And the second is that going lower did not produce significant changes in the size of the
particles. As a result, with this process the smallest particles I was able to produce, all
things considered, were between 1 and 2 microns. As such, this technique is not suitable
for making nanoparticles, but modifications such as using a probe sonicator could make
that possible in the future. Also, the largest particles I was able to produce were nearly 30
microns, and this could be achieved with high PLG % such as 12% wt/wt, low
homogenization such as 7,000rpm and settling via gravity (let tube sit for 10 minutes on
the lab bench and then remove supernatant). Resveratrol particles were usually larger than
30 um, but they were a special case as I outlined in this dissertation.
The length of time for evaporation/extraction and the bath volume are also very
important to particle fabrication. Extraction rate can affect the drug loading of particles
which was a major source of investigation of Maddie Spetz, a former student in the lab.
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We initially added an emulsion with 0.6 mL of DCM 4 mL PVA to an extraction bath of
16 mL. This is a DCM vol% of 3 which is higher than its solubility in water (around 2%).
As a result, we increased this to 80 mL in the extraction bath which ensures DCM is always
soluble. In addition, we found that extracting for 1 hour was sufficient for evaporating away
DCM (which is highly volatile) and 1 hour extraction is now the standard of practice.
Add organic solution slowly to the PVA during the emulsion step. PVA should be
measured out and put in a 50 mL centrifuge tube and PLG solution should be handled with
a Hamilton syringe. After you have vortexed the vial, take up the organic solution into the
Hamilton syringe. Then start the homogenizer and begin adding the solution slowly into
the 50 mL tube. It is most likely that the organic solution and PVA can be added at the
same time and then begin homogenization. However, I never studied this possibility
extensively so future students can take that question on if they wish. Most literature
suggests adding the organic phase slowly.
These are my major pieces of wisdom. There are many parameters that can be
controlled in this process and sometimes it is important to run your own experiments to
understand how they affect the system. If you have any questions contact me at
chris.isely11@gmail.com. If you are a future student in the lab, good luck with your
experiments, and thank you for reading until the end!
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APPENDIX B
MANUSCRIPT PERMISSIONS

Figure B.1 Copyright permissions for publications reprinted in this
dissertation.
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